SUMMARY  Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is available as soon as there are survivors. The COVID-19 pandemic represented the first large-scale opportunity to shed light on the mechanisms of action, safety, and efficacy of CP using modern evidence-based medicine approaches. Studies ranging from observational case series to randomized controlled trials (RCTs) have reported highly variable efficacy results for COVID-19 CP (CCP), resulting in uncertainty. We analyzed variables associated with efficacy, such as clinical settings, disease severity, CCP SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antibody levels and function, dose, timing of administration (variously defined as time from onset of symptoms, molecular diagnosis, diagnosis of pneumonia, or hospitalization, or by serostatus), outcomes (defined as hospitalization, requirement for ventilation, clinical improvement, or mortality), CCP provenance and time for collection, and criteria for efficacy. The conflicting trial results, along with both recent WHO guidelines discouraging CCP usage and the recent expansion of the FDA emergency use authorization (EUA) to include outpatient use of CCP, create confusion for both clinicians and patients about the appropriate use of CCP. A review of 30 available RCTs demonstrated that signals of efficacy (including reductions in mortality) were more likely if the CCP neutralizing titer was >160 and the time to randomization was less than 9 days. The emergence of the Omicron variant also reminds us of the benefits...
of polyclonal antibody therapies, especially as a bridge to the development and availability of more specific therapies.

**KEYWORDS** COVID-19, convalescent plasma, randomized clinical trial, propensity score-matched, neutralizing antibodies, viral neutralization tests

**INTRODUCTION**

In the first 21 years of the 21st century, humanity has experienced six major multinational epidemics. The agents involved were severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), influenza A(H1N1) virus, Ebola virus, Zika virus, and SARS-CoV-2. For the five most lethal of these outbreaks, the response included the use of convalescent plasma (CP) (reviewed in references 1 and 2), and it was considered for the less lethal sixth (Zika virus). The attraction of CP is that it is readily available as soon as there are convalescing survivors, that unlike drugs or monoclonal antibodies it needs no development, and it is polyclonal, affordable, and deployable even in resource-poor countries. Despite suffering from some logistical hurdles (dedicated collection, testing, and handling procedures, heterogeneity, standardization of the therapeutic dose, blood type matching, and intravenous delivery), CP has been proposed as a first-line response to new pandemics (3) and was deployed during the COVID-19 pandemic in March 2020 in countries that experienced the early waves of disease, such as China (4, 5) and Italy (6). The relatively low COVID-19 case-fatality rate (compared to the other epidemic agents noted above) allowed for testing of CP across a wider spectrum of disease severity.

While in early 2020 most clinical use was reported in case series or small phase II clinical trials (7), beginning in late March 2020, the U.S. expanded access program (EAP) generated a large and robust treatment data set, with insights into safety and optimal use. This database provided the first clear evidence that CP is safe, which was important given that early in the pandemic there were significant concerns about antibody-dependent enhancement (8). Later, an analysis of the first 3,082 patients within the EAP database provided evidence that associated early administration of high-titer COVID-19 CP (CCP) to nonventilated hospitalized patients with reduced mortality (9). Before the FDA granted emergency use authorization (EUA), the U.S. EAP provided CCP to as many as 94,287 patients.

During the past year, many studies employing either randomized control (RCTs) or propensity score-matched (PSM) controls have been published: as of 28 January 2022, PubMed, which is also indexing studies on the medRxiv prepublication server, had reported 30 RCTs and 13 PSM studies on CCP, and the ClinicalTrials.gov database had reported 24 more RCTs that were completed, active, or recruiting across several continents. RCTs and PSM studies reported so far have had largely opposite outcomes, with most but not all RCTs finding little overall effect on mortality and the PSM studies and many smaller trials reporting mortality benefits. Several RCTs did not have mortality as a primary endpoint or it was part of a composite endpoint (5, 10–12). These disparate results have led to confusion for both the public and clinicians, leading to reduced enthusiasm for the use of CP, in part because RCT data are more influential in affecting the opinion of many physicians, specialty societies, and government regulators.

As with any other medical treatment, several key factors should be taken into account when evaluating a trial, including the indication (which can be estimated by timing or clinical severity), the therapeutic dose, and the intended outcomes. The choices made by the trial designers determine whether the trial will demonstrate clinical benefit. While much attention is appropriately focused on the performance features of clinical trials (sample size, fidelity to randomization, appropriate analysis), the biological rationale for the hypothesis being tested is critically important but not always taken into account.

**THE INDICATION**

While it would be desirable to have a single drug that works at any disease stage, it was not reasonable to expect neutralizing antibody (NAb)-based treatments such as CCP to have a significant effect in later stages of disease. COVID-19 is now well defined as a disease...
with two stages, an initial viral phase characterized by flu-like and upper and lower respiratory symptoms, followed, in severe cases, by an inflammatory phase that is characterized by inflammation-driven damage to multiple organ systems, including the lungs, which can impair gas exchange and cause life-threatening hypoxia and damage to multiple organs, including the brain and blood vessels (13). Accordingly, lack of endogenous NAb at baseline has been associated with a higher risk of viremia, but Marconato et al. showed that CCP recipients benefit from high-titer CCP even after adjustment for their endogenous NAb (14). Specific intact antibodies in CCP are expected to neutralize SARS-CoV-2 in the intravascular system and, in some patients, prevent progression from early to severe and life-threatening disease (as seen in animal models [15–17]). However, this antiviral therapy cannot be expected to reverse the inflammatory phase of the disease or neutralize infectious viruses invading the extravascular system. Thus, the impact of CCP in COVID-19 is similar to that seen in influenza, a disease in which antivirals are effective early in disease but have no effect in later stages when the symptomatology stems largely from the inflammatory response. The rationale for administering CCP as early as possible in the course of COVID-19 stems from the neutralization stoichiometry itself: the larger the number of actively replicating virions in the body, the higher the NAb dose needed for neutralization (18). Some uncontrolled studies have reported a lack of association between early intervention and outcomes (19, 20), but in these studies, the level of NAb or the overall anti-Spike antibody level in the infused CCP was unknown, leaving room for alternative explanations.

At the beginning of the pandemic, some investigators and opinion leaders, riding the wave of CCP successes in anecdotal reports in the media and small case series, introduced CCP to the general public as a panacea for any patient with COVID-19, including life-threatening cases, leading to confusing messaging: after reports of failure in severely ill patients emerged, opinions became polarized and the debate became anything but scientific (21). We use the word “failure” with care and considerable nuance, since negative trials can be very important in teaching us about populations that do not benefit from CCP or variables that affect its efficacy. In clinical trials, the indication (i.e., the baseline clinical setting) has been variously defined by patient status (outpatient versus presenting to the emergency room versus hospitalized versus intensive care unit [ICU] admitted), disease severity (using the 5-category COVID-19 Outpatient Ordinal Outcome Scale [22], a 6-category ordinal scale [12], a 7-category COVID-19 severity scale [23], the WHO 8-category [24] or 11-category [25] ordinal scale, or pneumological scores such as sequential organ failure assessment [SOFA]), the time elapsed before recruitment (also variably defined as from molecular diagnosis, from onset of hospitalization, from diagnosis of pneumonia, or from onset of symptoms), or by serological status (presence of antibodies or the ability to neutralize SARS-CoV-2). This variability in inclusion criteria for studies has resulted in marked heterogeneity in recruited patients. As shown by the CONTAIN trial (where those with shorter symptom durations did worse), symptom duration can be a poor indicator of “early” disease but may actually serve to indicate of severe, rapidly progressing disease (26). Disease severity marked by WHO score as opposed to symptom duration may be a more accurate tool for capturing “early” disease, as supported by the positive results with CCP in patients with low WHO scores, as summarized in Fig. 1.

The vast majority of SARS-CoV-2 infections are mildly symptomatic, so when dealing with outpatients (WHO categories 1 to 3; the strata which are most likely to benefit from NAb-based therapies), the number needed to treat (NNTT) in order to prevent a single hospitalization or death can be very large and even larger if vaccinees are recruited. In order to be economically and logistically sustainable, it seems wise to focus on those outpatients having risk factors for disease progression, as was done with COVID19 monoclonal antibodies (MAbs). This approach was pursued by C3PO (27) and NCT04479163 but not other outpatient RCTs (CoV-Early [28], CoVVeRT [29], CSSC-004 [30]). A special category is represented by outpatients recruited at the time of emergency room (ER) attendance (e.g., in C3PO [27]): they should be considered as at the border between outpatients and inpatients and hence not aggregated in outpatient meta-analyses. Among outpatients not recruited at the ER, clinical benefit has been shown up to 6 days since onset of symptoms (e.g., in the CSSC-004 RCT [30]). No benefit of CCP over fresh frozen plasma (FFP) has been proven in the single
RCT of postexposure prophylaxis (CSSC-001) at preventing infection or symptomatic disease, but the study was not powered to detect a reduction in hospitalization (31).

For inpatients (WHO categories 4 to 9), clinical benefit from CCP is more likely for those in categories 4 and 5, since from category 6 on, the patients require high-flow oxygen and hence have significant respiratory failure.

THE THERAPEUTIC DOSE

Determining the effective dose of CCP is difficult in a pandemic because the antibody assays and other tests needed to assess the potency of any antibody product take time to be developed. In practice, the effective dose is the product of multiple factors, none of which is fully standardized.

The first factor is the concentration of the NABs as measured by a viral neutralization test (VNT). At the beginning of the pandemic, only a few laboratories equipped for biosafety level 3 (BSL3) or higher studies could run a VNT using authentic live SARS-CoV-2 virus: the procedure was time-consuming (3 to 5 days), and the reports were operator dependent. Nowadays, the availability of Spike-pseudotyped viruses which can be managed under the more widely available BSL2 laboratories or cell-free ACE-2 competition assays, combined with automated (e.g., luminescence-based) readings, have standardized outcomes and shortened turnaround times (32): however, harmonization between different assays is still a work in progress (33). The VNT differs according to the type of replication-competent cell line, the viral isolate used for the challenge (which is critically important when the virus is mutating rapidly, as has been the case with emergence of variants of concern [VOCs]), the multiplicity of infection (i.e., the ratio between the viral inoculum—assessed with different measuring units—and the number of replication-competent cells within each
well), the detection system (optic microscopy for cytopathic effect, immunostaining, quantitative PCR, or luminometer for engineered pseudoviruses), and finally, the threshold of neutralization (50% or 90%). The DAWN-plasma (34), C3PO (27), and REMAP-CAP (35) RCTs provide clear examples of such heterogeneity, with up to 4 different VNTs used at different participating laboratories/countries within the same study (see Table 1). It was not until August 2020, when many trials were already under way, that the FDA EUA 26382 defined high-titer CCP on the basis of correlation with a reference standard, the Broad Institute live-virus, 5-dilution VNT, as a 50% inhibitory dilution (ID50) of 1:250 or more (https://www.fda.gov/media/141481/download), and exclusive use of high-titer CCP was formally recommended by the FDA only on 9 March 2021. Table 1 summarizes the key variables in VNTs employed to date in CCP RCTs. Published trials have varied greatly in their approaches to antibody quantification, whether in measured transfused CCP units or in recipients. Several RCTs performed NAb titration but with highly heterogenous methods, which makes comparability of doses across studies difficult. Table 1 attempts to reconcile doses across those trials, suggesting that they actually differed more than is apparent by inspection of raw titers.

Despite these uncertainties, we can make estimates of likely effective doses based on the available clinical experience thus far. The lack of utility from low-titer (1:40) CCP in moderate COVID-19 was confirmed by the PLACID trial (10). As long as a clear therapeutic dose is not identified, given that a 250-mL unit of transfused CCP is diluted into the ~2.5 L of plasma in the recipient, it seems prudent to transfuse units containing NAb titers at least 10-fold higher than the NAb titer measured before transfusion in recipient serum. Similarly, the ConCOVID RCT showed that CCP units having NAb titers similar to those of the recipients (1:160) did not confer a clinical benefit (36). CCP units with an adequate NAb titer (nowadays estimated at >1:160) are more easily found among older males who recovered from a previous symptomatic COVID-19 requiring hospitalization (37, 38); unfortunately, such donors were poorly represented in the first donation waves, which tended to obtain CCP from younger donors with mild disease and, presumably, lower NAb titers (10).

Many trials have relied on high-throughput semiquantitative or qualitative assays with a poor to moderate relationship with NAb titers. Harmonization of such high-throughput assays using the WHO International Standard of binding arbitrary units (BAU) is now possible (39). Although most trials performed a correlation analysis between VNTs and high-throughput serological assays, in many cases, the CCP units were tested only with the latter without validation, as was the case with 66% of the patients in the PlasmAr trial (12). This procedure risks an incorrect evaluation of the neutralizing CCP activity. Another cause for discrepancies in outcomes could be that although IgM, IgG, and IgA are all capable of mediating neutralization, VNT titers correlate better with binding levels of IgM and IgA, than they do with IgG (40). In contrast, routinely used high-throughput serological assays quantify only IgG, including nonneutralizing IgGs, whose potency against SARS-CoV-2 has not been established. Trials should preferentially use VNTs to assess the serostatus of transfused units and not rely on high-throughput serology. As for any other medicinal product, CCP exhibits a dose-response relationship, which is also evident when high-throughput assays are used. In the subgroup analysis of the EAP, a gradient of mortality was seen in relation to IgG antibody levels in the transfused CCP. In the subgroup of patients who were not receiving mechanical ventilation, death within 30 days after CCP transfusion occurred in 81 of 365 patients (22.2%; 95% confidence interval [CI], 18.2 to 26.7%) in the low-titer group, 251 of 1,297 patients (19.4%; 95% CI, 17.3 to 21.6%) in the medium-titer group, and 50 of 352 patients (14.2%; 95% CI, 10.9 to 18.2%) in the high-titer group. Depending on the statistical model, the risk ratio (RR) for 30-day mortality in high-titer CCP recipients compared to low-titer CCP recipients ranged from 0.64 to 0.67, with an upper 95% confidence bound of 0.91 (8). Similarly, the large retrospective PSM study from Hospital Corporation of America (HCA) Healthcare-affiliated hospitals reported a 0.2% decreased risk of mortality for every 1 unit of signal-to-cutoff ratio (S/CO) serology level (41).

An additional limit is testing NAbs only at the time of first donation (e.g., in ConCOVID [36]) while leaving donors opportunities to repeat their donations for months: given the
| Virus RCT (acronym/first author) | Cell line | No. of cells seeded/well | Virus lineage | Virus/well | MOI | Length of incubation | Assay readout | Threshold | Protocol reference |
|---------------------------------|-----------|--------------------------|---------------------------------|------------|-----|----------------------|--------------|-----------|-------------------|
| **Authentic live SARS-CoV-2**   | Vero B6   | 12,000                   | SARS-CoV-2/human/TV/PAVMA 10734/2020 (D614G) | 100 TCID<sub>50</sub> | 0.01 | Until the CPE became evident | CPE          | Last serum dilution that inhibited SARS-CoV-2 CPE by 90% | 126 |
| NeCoV-NET; NCT04393727 (TSUNAMI) | Vero B6   | NA                       | NA                              | 100 PFU    | NA  | 3 days               | CPE          | N-protein ELISA | 127 |
| Broad Institute on a high-throughput platform (BROAD PRNT); part of NCT04355767 (C3PO) | Vero B6-TMPRSS2 | 10,000                  | SARS-CoV-2 live virus (D614) | 48 h       | CPE | N-protein ELISA | CPE          | Reciprocal of the highest dilution resulting in a reduction of ≥50% of infected cells (PRNT<sub>50</sub>) | 11 |
| Vero E6                           | 10,000                | SARS-CoV-2/human/ITA/PAVMA 10734/2020 (D614G) | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 127 |
| **Australian part of NCT02735707 (REMAP-CAP)** | Vero B6 | 1,800                    | 2019-nCoV/USA-WA1-2020 | 100 TCID<sub>50</sub> | 0.01 | 48 h | Triplex Cq-SARS-CoV-2 1RT-PCR test, EUA200510 | 128 |
| Vero E6-TMPRSS2                   | 10,000                | SARS-CoV-2 live virus (D614) | 48 h | CPE | N-protein ELISA | CPE          | Reciprocal of the highest dilution resulting in a reduction of ≥50% of infected cells (PRNT<sub>50</sub>) | 11 |
| **Canadian part of NCT02735707 (REMAP-CAP)** | Vero B6 | 20,000                  | SARS-CoV-2 live virus (D614) | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 135 |
| Vero CCL-81                       | 5,000                 | 2019-nCoV/USA-WA1-2020 | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 134 |
| **Spike pseudotyped viruses**    | Vero B6   | 1,800                    | 2019-nCoV/Italy-INM81 | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 128 |
| **Viral Research Institute (VI) pseudovirus neutralization; part of NCT04355767 (C3PO)** | Vero B6 | 2,000                    | hCoV/Australia/VIC01/2020-11 | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 136 |
| Vero E6                           | 5,000                 | hCoV/Australia/VIC01/2020-11 | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 136 |
| NCT04383533 (PlasmA)             | Vero CCL81            | 20,000                   | SARS-CoV-2 live virus (D614) | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 136 |
| **Australian part of NCT02735707 (REMAP-CAP)** | Vero B6 | 1,800                    | 2019-nCoV/USA-WA1-2020 | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 136 |
| Vero E6                           | 10,000                | SARS-CoV-2 live virus (D614) | 48 h | CPE | N-protein ELISA | CPE          | Reciprocal of the highest dilution resulting in a reduction of ≥50% of infected cells (PRNT<sub>50</sub>) | 11 |
| **Canadian part of NCT02735707 (REMAP-CAP)** | Vero B6 | 20,000                  | SARS-CoV-2 live virus (D614) | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 134 |
| Vero CCL-81                       | 5,000                 | 2019-nCoV/USA-WA1-2020 | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 134 |
| **Spike pseudotyped viruses**    | Vero B6   | 1,800                    | 2019-nCoV/Italy-INM81 | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 128 |
| **Viral Research Institute (VI) pseudovirus neutralization; part of NCT04355767 (C3PO)** | Vero B6 | 2,000                    | hCoV/Australia/VIC01/2020-11 | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 136 |
| Vero E6                           | 5,000                 | hCoV/Australia/VIC01/2020-11 | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 136 |
| NCT04383533 (PlasmA)             | Vero CCL81            | 20,000                   | SARS-CoV-2 live virus (D614) | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 136 |
| **Australian part of NCT02735707 (REMAP-CAP)** | Vero B6 | 1,800                    | 2019-nCoV/USA-WA1-2020 | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 136 |
| Vero E6                           | 10,000                | SARS-CoV-2 live virus (D614) | 48 h | CPE | N-protein ELISA | CPE          | Reciprocal of the highest dilution resulting in a reduction of ≥50% of infected cells (PRNT<sub>50</sub>) | 11 |
| **Canadian part of NCT02735707 (REMAP-CAP)** | Vero B6 | 20,000                  | SARS-CoV-2 live virus (D614) | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 134 |
| Vero CCL-81                       | 5,000                 | 2019-nCoV/USA-WA1-2020 | 100 TCID<sub>50</sub> | 0.01 | 3 days | CPE          | N-protein ELISA | 134 |

(Continued on next page)
| Virus RCT (acronym/first author) | Cell line | No. of cells seeded/well | Virus lineage | Virus/well | MOI | Length of incubation | Assay readout | Threshold | Protocol reference |
|--------------------------------|-----------|--------------------------|---------------|------------|-----|----------------------|---------------|-----------|-------------------|
| NCT04344535 (Bennett-Guerrero) | NA        | NA                       | PRNT and pseudovirus | NA         | NA  | NA                   | NA            | NA        | 57                |
| NCT04660040 (COP20)           | Vero B6   | 1,000                    | Pseudovirus     | 200 PFU    | NA  | 8h                   | Indirect immuno-fluorescence measured by Tegyhos Plate Runner HD | No of infected cells were quantified and normalized to that of virus incubated without plasma. IC_{50} values were calculated using normalized data and a nonlinear fit with variable slope |
| NCT04621123 (COnV-ert)       | HEK293T/ACE2 | 10,000                  | HIV reported pseudovirus | 200 TCID_{50} | 0.02 | 48h                   | Luminometer ID_{50} was calculated by plotting and fitting the log of plasma dilution vs normalized response |
| NCT04364737 (cONTAIN)        | Vero      | NA                       | VSV pseudovirus  | NA         | NA  | 7h                   | Automated enumeration of GFP-positive cells | IC_{50} |

*Information was retrieved from the original article (including the supplementary appendix). NA, not available (details could not be retrieved); IC, inhibitory concentration; NT, neutralization titer; PRNT, plaque reduction neutralization test; VNT, virus neutralization test; MOI, multiplicity of infection; VSV, vesicular stomatitis virus; aa, amino acids; TCID_{50}, 50% tissue culture infective dose; CPE, cytopathic effect; PRNT_{50}, plaque reduction neutralization test of 50%; IC_{50}, 50% inhibitory concentration; ID_{50}, 50% infective dose; C_{t}, threshold cycle; absIC_{80}, absolute 80% inhibitory concentration; MN absIC_{50}, absolute 50% inhibitory concentration; RLU, relative light units; OD, optical density; rRT-PCR, real-time reverse-transcriptase polymerase chain reaction.

*These data not reported in the reference, so the corresponding author was contacted.
expected decline of NAb levels over time in convalescents, this could have overestimated the actual dose received in units collected later.

The NAb titer (or total IgG levels as measured by surrogate assays) describes only one factor involved in defining the real therapeutic dose in that it represents the concentration of just one (likely the main) active ingredient. But CCP contains additional antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC), complement activation, and phagocytosis of viral particles, functions that can each contribute to its antiviral effects (42). At this time, the relative importance of NAbs versus the other antibody activities is not understood, but hopefully, retrospective analyses that correlate CCP efficacy with these activities will reveal additional variables that need to be considered in choosing optimal CCP units. This has relevance when assessing interfering factors; e.g., the impact of pathogen reduction technologies (PRT) on NAbs has experimentally been shown to be apparently minimal (43, 44), but the impact on Fc-dependent functions (such as ADCC) is still to be investigated and could be relevant for some PRTs (45) used, e.g., in TSUNAMI (46), NCT04356534 (47), ConPlas-19 (48), and ConV-ert (29). In this regard, we note that an early study reported that methylene blue reduced the protective function of antibodies to pneumococcus by interfering with glycosylated domains, raising concerns that it could affect Fc function (45). Of relevance, the various pathogen-reduced plasma units went through clinical evaluation for assessment of their hemostatic activity linked to coagulation factors or, at best, Fc binding to receptors (49), not their immunological activity; furthermore, none of the photochemical processes used for CCP is used in the field of plasma fractionation, and therefore we cannot make inferences from pharmaceutical-grade immunoglobulins.

The therapeutic dose of NAb is a product of its concentration in the infused CP multiplied by the overall infused CP volume, adjusted to the recipient body weight to take account of dilution into the blood volume and tissues. RCTs have varied in the provision of volume per unit (200 to 300 mL) and, most importantly, in cumulative volume per patient (1 to 4 units) and in extent of exposure to diverse antibodies from various CCP donors, and no published trials have adjusted levels of NAbs by recipient body weight (or, when attempts have been performed, they referred to the historical 10- to 15-mL/kg dose derived from the treatment of hemorrhagic coagulopathies (50)). A failure of CCP to improve outcomes when 200 mL of CCP with a 1:160 NAb titer is provided to a patient who weighs 120 kg represents quite a different scenario from failure of a 600-mL transfusion of CCP with a 1:640 NAb titer to produce improvement in a 60-kg patient. But these central issues in dosage have not been considered in the RCTs published so far.

Finally, antibodies other than NAbs can play a prominent role in viral clearance. Bahnan et al. have shown that CCP and anti-Spike MAbs induce phagocytosis but with diminishing returns when the antibody concentrations become high; activation and inhibition of phagocytosis are independent of neutralization potential, and humanized ACE2 mice are protected from intranasal challenge by nonneutralizing antibodies (51).

**RELEVANCE OF CCP TO THE VIRAL VARIANT**

Albeit not formally demonstrated, CCP manufactured by pooling ABO-matched units from many different donors (e.g., in PlasmAr (12)) theoretically should have greater polyclonality of NAbs than repeated CCP doses from a single donor (e.g., in CAPSID (52)) and should provide higher efficacy against viral variants. Nevertheless, pooling typically occurs among donors attending the same blood bank, making donor exposure to different variants less likely.

An analysis of potential variables associated with CCP efficacy associated near-sourcing with reduced mortality; the efficacy of CCP in reducing mortality fell sharply when the CCP source was more than 150 miles from where it was used (53). This finding suggests that SARS-CoV-2 variants at some geographic locations create antibody responses in CCP that are not effective against other variants at different locations (54, 55). Even though CCP is often standardized for the NAb titer to the Spike protein, the VNT could use a nonrelevant viral strain or miss major functional differences for the antibody response (42). This finding has implication for RCTs that use nationally sourced (centralized) CCP, since the attempt to standardize the therapeutic units centrally could inadvertently reduce CCP efficacy if hospitals use.
CCP obtained from distant loci. For example, in the C3PO RCT, which was conducted in 21 U.S. states, 95% of the donor CCP was collected in either Chicago or Denver; since only 4 of the 48 centers were in Illinois or Colorado, most CCP usage had to be from remote sources (27). The same concern applies to large multinational RCTs such as REMAP-CAP (35). In contrast, the NCT04359810 RCT in New York and Brazil, which found a beneficial effect of CCP on mortality, used CCP locally sourced in New York, and its efficacy against P.1 was tested to ensure efficacy at the other recruiting center in Brazil (11).

Although also not formally demonstrated during clinical trials, it is reasonable to assume that CCP collected during early pandemic waves could be less effective against currently circulating variants of concern (56). RCTs whose recruitment was protracted across multiple pandemic waves (e.g., ConPlas-19 [48] and TSUNAMI [46]) and which relied on CCP collected and banked months earlier could have inadvertently used CCP with reduced activity against the SARS-CoV-2 strains circulating in the community when the therapy was administered. No CCP study to date has ever annotated or retrospectively performed SARS-CoV-2 sequencing on CCP donors or on patients to identify the underlying variant; matching of the convalescent donor and the recipient for viral variant has never been formally achieved. Hence, both geography and time of collection of the CCP are important variables when considering the efficacy of the treatment.

THE INTENDED OUTCOMES

Most trials (CONTAIN [26] and PassItOn being exceptions) have used composite endpoints or specialty scores (e.g., SOFA) rather than progression in the simple WHO ordinal scale or mortality, and many were stopped because of apparent futility at a time when they may have been underpowered to detect significant benefit. As represented in Fig. 2, several studies have reported overall negative results (Fig. 2A) despite the presence of positive signals of efficacy just barely missing statistical significance (Fig. 2B and C). The significance level (i.e., $P = 0.05$) is largely a socially constructed convention for rejecting the null hypotheses, but it has often been misinterpreted as a measure of reality by many individuals not familiar with the nuances of statistics. For example, some CCP studies have concluded that a difference that did not achieve a $P$ value of $<0.05$ indicated an absence of difference, even when mortality in the CCP arm was $\sim$20 to 40% lower than in controls (11, 48, 52, 57). This reasoning has played a central role in the polarized views of CCP efficacy and has impeded subsequent studies from drilling down on positive effects that were observed. The dogged pursuit of statistical significance, viewed as a measure of reality, instead of the actual reality demonstrated by the data during a public health emergency dealt a serious blow to studies of CCP and created significant confusion for clinicians. It is also important to understand that RCTs are powered to be less tolerant of type I errors than type II errors, which are conventionally set at 0.05 and 0.20, meaning that a type II error is expected four times as often as a type I error. This statistical convention can contribute to the absence of significance in studies that were set up early in the pandemic, when there was little information on expected effects for the various patient populations studied, when power estimates were only guesses, and when the enrolled patients were so heterogenous that only subgroups were likely to have responded to CCP treatment. Many studies were originally designed to enroll inpatients at any disease stage, and it should be no surprise that subgroup analyses on the groups that were later demonstrated to be more likely to benefit from CCP (e.g., early treated, sero-negative patients, those receiving high NAb titer) were underpowered to reach statistical significance, as shown by orange color predominance in Fig. 2C. Nevertheless, favorable trends are a shared feature across such trials (5, 11, 12, 27, 48, 50, 52, 57, 58).

Rigid adherence to primary outcomes that were often fixed in the early days of the pandemic, when information about disease stage and quality of CCP associated with efficacy were not understood, has contributed further to the confusion. When these outcomes were not met, trials were considered failures, even though there were often signals of efficacy in the data that were not considered as valuable since these had not been prespecified, even when they made biological sense. For example, in the New York-Brazil RCT cited above, CCP did not lower the primary endpoint of clinical status on an ordinal scale, but the statistically
FIG 2 Simplified graphical representation of CCP RCTs and large uncontrolled trials reported to date, plotted according to earliness of intervention and NAb titers in CCP. (A) Green text indicates trials which met the primary endpoint with statistical significance; orange text indicates trials which failed to meet the primary endpoint but showed statistically nonsignificant trends in favor of CCP; red text indicates trials which failed to show and benefit from CCP in the primary endpoint. (B) Green text indicates trials which showed overall mortality benefit from CCP; orange text indicates trials which showed mortality benefit from CCP; black text indicates trials which showed no mortality benefit from CCP. (Continued on next page)
significant halving of mortality was acknowledged in the abstract. Would it have made sense to ignore the strong effect of CCP on mortality in this trial just because mortality was not selected as a primary outcome? RCTs of MAbs (59) and dexamethasone (60) were designed to achieve a tiny 6% and 4% reduction in mortality, respectively, while several CCP RCTs failed because their initial assumption in the magnitude of reduced mortality was more optimistic (e.g., TSUNAMI [46]).

Another misunderstood endpoint is viral clearance, defined as the conversion of nasopharyngeal swabs (NPS) from positive to negative for PCR evidence of SARS-CoV-2 in CCP-treated patients. While there was early and robust evidence for this effect from CCP (4, 10), the sampling of NPS too late after CCP treatment, when the endogenous immune response had also mounted in the control arm, could miss differences.

ANALYZING CONFLICTING OUTCOMES IN INDIVIDUAL RCTs

Keeping the factors discussed above in mind, we have analyzed individual RCTs in detail. At the very beginning, many historically or internally controlled observational studies showed clinical benefit from CCP (4–6), and this led the FDA to issue an EAP in March 2020 that was converted into an emergency use authorization (EUA) on 23 August 2020. The largest observational study is the U.S. open-label EAP (NCT04338360) led by Joyner et al., which enrolled 105,717 hospitalized patients with severe or life-threatening COVID-19 from 3 April to 23 August 2020 (61). In an analysis of the effect of antibody in CCP performed independently of the results cited above (8) and using a NAb titer in an overlapping but nonidentical group of EAP patients, the FDA showed that the 7-day mortality in nonintubated patients who were younger than 80 years of age and were treated within 72 h after diagnosis was 6.3% in those receiving high-titer CCP and 11.3% in those receiving low-titer CCP (https://www.fda.gov/media/142386/download).

In a later analysis of a larger (n = 35,322) subset of EAP patients (including 52.3% in the ICU and 27.5% receiving mechanical ventilation), the 7-day mortality rate was 8.7% in patients transfused within 3 days of diagnosis but 11.9% in patients transfused ≥4 days after diagnosis; similar findings were observed in 30-day mortality (21.6% versus 26.7%) (62). A similar halving of 28-day mortality was reported in inpatients treated within 3 days of hospitalization in large cohort studies from Argentina (18.1% mortality in 3,113 patients transfused within 3 days compared to 30.4% in 1,380 transfused at 3 to 7 days and 38.9% in 226 transfused after 7 days) (63) and Italy (14% mortality in 1,571 CCP-treated patients versus 25% in a synchronous CCP-untreated local cohort) (64). The major criticism of these results is that controls were neither randomized nor PSM; hence, a difference in treatment outcome between treated and untreated groups may be caused by a factor that predicts treatment rather than by the treatment itself. However, importantly, NAb titer analysis was retrospectively done, both patients and physicians were unaware of the NAb content in the CCP units used, the results are what would have been expected from the experience with antibody therapy, and multivariate models were used to adjust for potential confounders (1). Additionally, given the outline of an optimal use case with these data and the earlier underpowered RCT by Li et al. (5), it is unfortunate that due to (i) lack of awareness and (ii) logistical burden associated with protocol adjustments, involving repowering and new patients’ recruitment criteria, later-treatment RCTs either continued or were initiated without modifications based on newly available evidence.

FIG 2 Legend (Continued)

showed mortality benefit from CCP in the subgroup of early arrivals or higher NAb titers; red text indicates trials which failed to show any mortality benefit from CCP. (C) Green text indicates trials which showed statistically significant mortality benefit from CCP (overall or in the subgroup of early arrivals or higher NAb titers); orange text indicates trials which showed statistical trends toward mortality benefit from CCP (overall or in the subgroup of early arrivals); red text indicates trials which failed to show any mortality benefit trend from CCP in any subgroup. Underlined text indicates large trials which were not RCT and for which NAb levels were inferred from high-throughput serology but are nevertheless reported as reference studies. Numbers in parentheses indicate the cumulative number of patients enrolled. Sources cited in the figure are references 9–12, 26–30, 34–36, 41, 46, 48, 50, 52, 57, 73, 76, 77, 113, 114, and 145.
The highest level of scientific evidence in primary clinical research stems from prospective PSM studies and RCTs. PSM studies (Table 2) balance treatment and control groups on a large number of covariates without losing a large number of observations. Unfortunately, no PSM study to date has investigated NAb titers by VNT or outpatients. Nevertheless, in two retrospective PSM studies from two different hospitals in New York, trends for improved outcomes in nonintubated patients and those treated within 7 days of hospitalization (hazard ratio [HR], 0.33) were observed (65, 66). These findings were later confirmed in a prospective PSM study from Houston (67, 68). Of interest, a retrospective PSM study from Providence did not show any benefit, but patients were treated at a median of 7 days after onset of symptoms (69). Another PSM study from Yale associated CCP with a 35% reduction in mortality (70). That study is notable in that it included patients on mechanical ventilation who would not normally be expected to benefit from CCP and the percentage of individuals receiving corticosteroids was very low since the study was conducted in the early days of the pandemic in the United States. Another PSM from the Washington, DC, area found a reduction in mortality with CCP use at both days 14 and 28, which reached statistical significance at the earlier date (71). Finally, a very large study from 176 community hospitals affiliated with HCA Healthcare confirmed substantial mortality reduction in hospitalized patients receiving CCP within 3 days of admission (72).

Since PSM accounts only for observed (and observable) covariates, and not latent characteristics, RCT remains the gold standard for highest-level evidence (Table 3). In the PlasmAr RCT, the small number of early arrivals (less than 72 h since symptom onset) showed superior primary and secondary outcomes in the CCP arm (n = 28) compared to the placebo arm (n = 11), but the minimal contribution of this group to the overall cohort (228 CCP and 105 placebo recipients) made the advantage disappear in the final outcomes at day 30 (12). In another Argentinean RCT of 160 outpatients older than 65 years of age with mild COVID-19 who were treated with CCP within 72 h, progression to severe COVID-19 was halved at day 30 (73). Similar findings were reported in outpatients without risk factors in CSSC-004 (30). An RCT from India reported that patients younger than 67 years treated at a median of 4 days after hospital admission manifested superior mitigation of hypoxia and survival in the CCP arm (74). Another RCT in Spain enrolling patients at less than 7 days of hospitalization showed four deaths in the control arm and none in the CCP arm (48). Similarly, the ConCOVID RCT showed reduced mortality in the CCP arm (36).

An additional complexity in recruitment to CCP trials is time to treatment. Clinical trials involve administrative requirements and consent procedures, and recruitment to an RCT further requires randomization, which may produce delays in treatment. CCP therapy requires cross-matching of blood types, ordering of the CCP, which may or may not be available on site, and setting up the transfusion. This inherent delay from randomization to infusion means that RCTs may build in a disadvantage for the CCP study arm in the few RCTs using control treatments (e.g., saline or fresh frozen plasma [FFP]), where controls may have received treatment earlier in the disease course; for example, FFP was used in controls only in NCT04346446 (58), NCT04359810 (11), NCT04344535 (57), COV-Early (28), and CSSC-004 (30) RCTs. ABO-compatible CCP units may be not readily available at the local blood bank, and recruited patients may have to wait for a compatible unit of CCP. These almost inevitable delays from randomization mean that CCP may be provided later in the illness than is ideal, and even if the trial intends to treat early, in practice it may not be possible unless the RCT is designed to deliver plasma immediately after randomization.

During a pandemic, moreover, delays in treatment are magnified. The accrual of severely ill patients in emergency departments and the overwhelmed or even collapsed health care systems can create long delays from arrival in the emergency room to treatment. In the absence of quick (antigenic or molecular) tests for SARS-CoV-2, the turnaround time for final confirmation of diagnosis with PCR, which must often be run in batches, can take several hours. All these factors are likely to impact the efficacy of CCP treatment. To shorten such time, fully screened CCP collected from eligible donors (75) could be safely administered within emergency departments shortly after admission and even before the patient reaches the ward.
| Study design | Location | No. of patients + controls | Median no. of days CCP given posthospitalization | Baseline recipient WHO score (2.67) | Transfused CCP vol (mL) | Statistically significant outcomes | Reason(s) for failure | Reference |
|-------------|----------|---------------------------|------------------------------------------|---------------------------------|----------------------|--------------------------------|---------------------|-----------|
| Retrospective | Mount Sinai, NY, USA | 39 + 156 | 4 | 5 (67%), 6 (10%) | 250 ± 250 | On day 14, oxygen requirements worsened in 17.9% of plasma recipients vs 28.2% of controls (aOR, 0.86). Survival improved in plasma recipients (aHR, 0.34). | No failure | 66 |
| | Providence, RI, USA | 64 + 177 | >2 (< 10 from onset of symptoms; median, 7) | 4 (70%), 5 (30%) | NA (2 units) | No significant differences in incidence of in-hospital mortality (12.5% and 15.8%; aHR, 0.93) or overall rate of hospital discharge (HR, 1.26; although increased among patients of ≥65 yrs). | Late usage | 69 |
| | Montefiore Medical Center, NY, USA | 90 + 258 | <3 (< 3–7 days from onset of symptoms) | 5–6 (< 24 h of mechanical ventilation) | 200 | Anti-S-IgG titer > 1:12,430 (median, 1:147,385); recipients < 65 yrs had 4-fold lower mortality and 4-fold lower deterioration in oxygenation or mortality at day 28. | No failure | 65 |
| | Washington, USA | 263 + 263 | <14 | NA | 245 (median) | Reduced 7-day (91 vs 198%) and 14-day (14.8 vs 23.6%) mortality but not 28-day mortality (P = 0.06), and longer hospitalization. | Late usage; control cohort was treated, on average, 29 days prior to the CCP cohort | 71 |
| | USA (176 HCA healthcare-affiliated community hospitals) | 3,774 + 10,687 | <3 vs 4–7 | NA | NA | Lower mortality (aHR, 0.71) and faster recovery. CCP within 3 days after admission, but not 4–7 days, was associated with a significant reduction in mortality risk (aHR, 0.53). CCP serology level was inversely associated with mortality when controlling for interaction with days to transfusion (HR, 0.998) but was not significantly in a univariable analysis. | No failure | 72 |
| | China | 163 + 163 | 23 | NA | 300 | Hospital stay in CCP group was significantly longer than that of matched control group (P < 0.0001). | Very late usage; more advanced disease in the CCP group (23 vs 15 days since hospital admission). | 140 |
| | Greece | 59 + 59 | 7 | ≥4 | 200–233 (days 1, 3, and 5) | Significantly reduced risk of death (HR, 0.04–13.6%), significantly better overall survival by Kaplan-Meier analysis, and increased probability of extubation (OR, 3.3). Higher levels of antibodies (as measured with Euroimmun or pseudorVNT) in CCP recipients were independently associated with significantly reduced risk of death. | No failure | 141 |
| | New Haven, CT, USA | 132 + 2,551 | <6 vs >6 days | Moderate to severe | Early CCP recipients, of whom 31 (40%) were on mechanical ventilation, had lower 14-day (5% vs 23%) and 30-day (38% vs 49%) mortality than a matched unexposed cohort, with nearly 50% lower likelihood of in-hospital mortality (HR, 0.52). Early plasma recipients had more days alive and ventilator-free at 30 days (> 3.3 days) and improved WHO scores at 7 days (< 0.8) and hospital discharge (< 0.9) than the matched unexposed cohort. | No failure | 70 |
| | USA | 143 + 823 (hematological cancer) | NA | NA | NA | Improved 30-day mortality (HR, 0.52; 95% CI, 0.29–0.92) among the 338 patients admitted to the ICU; mortality was significantly lower in CCP recipients than in nonrecipients (HR, 0.40). Among the 227 patients who required mechanical ventilatory support, mortality was significantly lower in CCP recipients than in nonrecipients (HR, 0.32). | No failure | 109 |
| Prospective | Houston, TX, USA | 136 + 251 | NA | 3 (9%), 4 (63%), 5 (18%), 6 (10%), 7 (1%) | 300 (1–2 units) | Reduction in mortality within 28 days, specifically in patients transfused < 72 h of admission with CCP with an anti-RBD titer of ≥ 1:1,350 (i.e., −80% probability of a live virus in vitro neutralization titer of ≥ 1:160[142]). | No failure | 67 |
| | | 341 + 594 | NA | NA | NA | Reduced 3-day mortality (aHR, 3.9 vs 10.7; aHR, 1.82 for controls) mortality in the CCP recipients with an anti-RBD titer of ≥ 1:1,350 within 72 h posthospitalization. Optimal window of 4 to 16 h to maximize benefit in 60-day mortality (4% vs 12.3%); 91% received CCP with an anti-RBD titer of ≥ 1:1,350. Median S/CO ratio of 24 using Ortho Vitros. | No failure | 68 |
| | Poland | 102 + 102 | NA | NA | NA | Lower mortality rate (13.7% vs 34.3%; OR, 0.25) related to time of first administration (12.2% at day 5, 21.5% at day 10); no significant differences in ICU stay, ventilator time, and hospitalization time. Earlier administration resulted in a ventilator being needed for a shorter length of time (P = 0.04). | No failure | 143 |
| | Brazil | 58 + 116 (kidney transplant recipients) | 6 from onset of symptoms | Mild and moderate | 200 | No differences in need for supplementary oxygen or mechanical ventilation at day 30. | Only 48% of CCP units were high titer; compared to nonsurvivors, a trend towards a higher proportion of survivors receiving higher-titer CCP | 144 |
| | Colorado (16 hospitals) | 188 + 188 | NA | 1 unit if < 90 kg, 2 units if ≥90 kg | Increased length of hospital stay in CCP-treated patients and no change in inpatient mortality compared to controls. In subgroup analysis of CCP-treated patients within 3 or 7 days of admission, there was no difference in length of hospitalization and inpatient mortality. | Coronate matching not achieved for subgroup receiving CCP < 3 days | 145 |

*None of these studies determined titers of NAbs in either donors or recipients using the VNT. PSM, propensity score matched; DPH, days posthospitalization; HR, hazard ratio; aHR, adjusted HR; OR, odds ratio; aOR, adjusted OR; RBD, receptor binding domain; S-IgG, secretory IgG. 

*These scores apply to both references 67 and 68.
| RCT identifier | No. of participants recruited | Control arm (in addition to BSC) | Median days before randomization | Baseline recipient 10-point WHO score(a) (24, 25) | Transfused CCP volume (mL)(25, 26) | Median NAb titer in CCP units | Median pretransfusion NAb titer in recipient | Main outcomes reported in abstract or conclusion | Likely reason(s) for failure | Signals of efficacy | Reference |
|----------------|-----------------------------|----------------------------------|---------------------------------|---------------------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------------------|---------------------------------|----------------------------|-----------|
| NCT04417015 (Libster) | 160 (out of 210) (1:1) BSC | normal saline | 39.6 h (from symptoms; <3 from ICU admission) | 2 (from symptoms) | 5 | 250 | NA | Progression to severe COVID-19 halved at day 30 | No failure | Main outcome | 73 |
| NCT04479163 (Jeong) | 30 (from symptoms) | 1:10 (from infection) | 39.6 h (from symptoms; <3 from ICU admission) | 5 | 250 | NA | NA | Duration of infection reduced by 4 days; mortality by 1/21 in CCP arm vs 8/29 in control arm | No failure | Main outcome | 73 |
| NCT04375098 (Bajpai) | 30 (from symptoms) | 1:10 (from hospitalization) | 30 | 5 | 200 | NA | NA | Immediate reduction of hypoxia and reduction in hospital stay, as well as survival benefit were encrusted in severe COVID-19 patients with ARDS aged less than 67 yrs; No significant difference in 28-day mortality (1.7% vs 2.0%); time from randomization to day 28 discharge (51.0% vs 36.6%) | No failure | Main outcome | 74 |
| NCT04421822 (ConCOVID) | 464 (1:1) BSC | 6 (from symptoms) | 4-5 | 5 | 200 | 1:40 | 1:90 | No benefit at day 28 | No benefit at day 28 | Very late usage; high rate of superinfection | 36 |
| NCT04419523 (ConPlasS19) | 350 (1:1) BSC | normal saline | 3 (29%), 4 (79%) | 8 (from symptoms) | 3 | 250-300 (methylene blue, 46.3%; reboflavin, 24%; procalcitonin, 19.6%; unknown, 165%) | 1:292 | NA | No significant differences in primary endpoints (proportion of patients in category 5, 6, or 7 [death] at 14 days) | No benefit at day 28 in mechanical ventilation, or prolonged hospitalization compared to CCP administration only in cases of clinical worsening or >7 days after enrollment | Underpowered; mortality primary endpoint set at just 15 days | None |
| NCT04370926 (Elvira-Balcells) | 581 (1:1) Late CCP | 6 (from symptoms) | 3-4 | 200 | 1:160 | 1:160 | 1:160 | No benefit at day 30 in death, mechanical ventilation, or prolonged hospitalization compared to CCP administration only in cases of clinical worsening or >7 days after enrollment | No benefit at day 30 | Underpowered; mortality primary endpoint set at just 15 days | None |
| NCT04383535 (PlasmAr) | 333 (2:1) BSC | normal saline | 5 | 500 (from a pool of up to 5 donors) | 1:300 | K<sub>pa</sub> | NA | No benefit at day 30 (16.2% vs 31.2%) | No benefit at day 30 (16.2% vs 31.2%) | Moderately late usage | Early arrivals (less than 72 h) showed superior primary and secondary outcomes in the CCP arm (n = 28) compared to the placebo arm (n = 11), but the limited contribution of this group to the overall cohort (120 CCP recipients and 101 placebo recipients) made the advantage disappear in the final analysis at day 30 (12) |
| NCT04365334 (WQhsin) | 401 (1:1) BSC | NA | 4 (9%), 5 (9%) | NA | 200 | 1:40 | 1:40 | No difference in requirement for ventilation, white blood cell count, LDH, CRP, procalcitonin, mortality rate at 28 days | Underpowered; the CP group was a higher-risk group with higher fibrin levels | Primary outcome measure was ventilation, which was required in 6 controls and 4 patients on CCP (9 vs 6.9%, 0.22) vs 20, P = 0.72; mean time on ventilation was 19.3 days in the control group vs 13 days in patients on CCP (P = 0.81) |
| NCT04346446 (Bajpai) | 291 (1:1) BSC | FFP | <3 (from symptoms) | 4-5 | 250 | 1:160 | 1:250 | No significant reduction in mortality or hospitalization | No significant reduction in mortality or hospitalization | Underpowered; measured with surrogate competitive assay (Enzyme-linked immunosorbent assay in FFP used in control arm (25)) | 58 |
| NCT04318136 (ECCOBY) | 1,158 (11) BSC | 9 (from symptoms; 2 from hospitalization) | 2-7 | 9 (81% got 2 units from different donors; 12% got 1 unit) | 2-7 | 250 | 3% seronegative | No significant difference in 28-day mortality or progression to invasive mechanical ventilation, closed for futility | Late usage | Risk ratio for patients randomized within 7 days of symptom onset was 0.92 in favor of CCP versus 1.04 in patients randomized later and 0.95 for those randomized within 5 days (personal communication), and analysis of severe-adverse event or death in patients <75 yrs; primary and secondary endpoints improved in methylene blue-treated CCP subgroup compared to controls (personal communication) |

(Continued on next page)
TABLE 3 (Continued)

| RCT identifier (acronym, first author) | No. of participants randomized (out of expected) | Control arm (in addition to BSC) | Median days before randomization | Baseline recipient COVID-19 serum* (2N, 2S) | Transfused CCP vol (ml, pathogen inactivation) | Median NAb titer in CCP units | Medium pretransfusion NAb titer in recipient | Main outcome(s) reported in abstract or conclusion | Likely reason(s) for failure | Signals of efficacy | Reference |
|---------------------------------------|-------------------------------------------------|---------------------------------|----------------------------------|---------------------------------------------|-----------------------------------------------|-------------------------------|-----------------------------------------------|---------------------------------|-----------------|----------------|
| NCT02730707 (REMAP-CAP)              | 2,011 (95% from UK)                              | CR + FFP                        | 0                                | 2 units (150 - 190 mL) within 48h          | ≥1:80 in Australia; NA in Canada, NA in UK and USA | NA                            | No significant difference in median organ support free days in hospital, mortality, or median number of days alive and free of organ support at day 21; closed for futility due to non-inferiority in primary endpoint | Very late usage | In the small no. of participants (n = 126) with immunodeficiency at baseline, CP demonstrated potential benefit (posterior probability of superior study 89.8%) | 94% reduction in primary end point in CCP group, which rises to 2.4% after exclusion of patients admitted on the index visit (P = 0.07); dyspnea emerged in 6.7% of controls but in 2% of those treated with CCP (P < 0.001); hospitalizations (including deaths) after the day of treatment were found in 12.8% of the CCP treated but in 19.6% of controls (P = 0.03); symptoms worsening after the first day occurred in 34.9% of CCP recipients but in 41.3% of controls (P = 0.05) | 27, 190 |
| NCT04155767 (GIPPO)                 | 511 (out of 900) with at least 1 risk factor associated with severe COVID-19 | BSC                              | 0                                | 200 mL unit (24 h apart)                   | 1:250 mL unit                                 | 1:641 ID<sub>50</sub> | NA                            | No significant difference in risk difference (1.9%); outcomes regarding worst illness severity and hospital free days were similar in the two groups | Very late usage | None | 125 |
| NCT04159810 (Gonzalez)              | 223 (21)                                        | BSC + FFP                       | 0                                | 9 from symptoms                            | One 200 - 250 mL unit                         | 1:160                         | NA                            | No difference in mortality at day 28 | Very late usage, beneficial factors in FFP used in control arm | Lower mortality (12.6% vs 24.6%) than with nonconvalescent plasma |  |
| NCT04158193 (Gonzalez)              | 190 (21)                                        | BSC + 1.5 mg/kg                 | 0                                | 12 from symptoms                           | Two 200 mL units                              | NA                           | NA                            | No difference in ventilator free days or mortality (2% vs 31%) at day 28, terminated after FDA issued EUA | Very late usage, beneficial factors in FFP used in control arm | None |  |
| NCT04144535 (Bennett-Garner)        | 74 (out of 500) (4:1)                           | BSC + FFP                       | 0                                | 9 from symptoms, 4 from hospitalization    | Two 200 mL units                              | 1:526                         | NA                            | No difference in ventilator free days or mortality (2% vs 31%) at day 28, terminated after FDA issued EUA | Very late usage, beneficial factors in FFP used in control arm | None |  |
| NCT04143910 (COPSID)                | 105 (1:1)                                       | BSC                              | 0                                | 7 from symptoms                            | Three units from same donor over 5 days (850 mL) | 1:160 (PRNT<sub>50</sub>) | 1:160 (PRNT<sub>50</sub>) | No significant difference in primary outcome (death due to respiratory failure; no longer fulfilling criteria for severe COVID-19) and secondary outcomes | Moderately late usage | All-cause mortality through 90 days was numerically lower in the CCP group than standard plasma group (27% vs 33%, P = 0.3); median time to discharge from hospital was 31 days (IQR: 16-64 days) in the CCP group and 51 days (IQR: 20-97 days) in the control group (P = 0.24) in the subgroup that received higher cumulative amount of Nabs, the primary outcome occurred in 56.8% vs 52.1%, with a better internal to clinical improvement, shorter time to hospital discharge, and better survival than that of the control group | 52 |
| NCT04147660 (PLACOV1D)              | 160 (1:1)                                       | BSC                              | 0                                | 10 from symptoms                           | Two 300- mL aliquots 2 days apart 1           | NA                           | NA                            | No difference in 28-day mortality, days alive, days of respiratory support, duration of invasive ventilator support or mechanical ventilation and other laboratory marker values on days 2, 7 and 14 | Very late usage |  | 125 |
| NCT04142954 (DAWN- plasma)          | 320 (21)                                        | BSC                              | 0                                | 7 from symptoms                            | Two 200- to 250- mL aliquots 1.2% followed by 2 units in 36h | NA                           | ≥1:320                         | No significant improvement in proportion of patients that required mechanical ventilation or had died at day 15 or 30 | Late usage | None | 34, 151 |
| NCT04142123. (CONVerS)              | 376 (out of 474) (1:1)                          | FFP                              | 0                                | 44 from onset of symptoms (outpatients)    | One 200 - 300 mL unit methylene blue inactivated | 1:1,379                         | 8.5% sararagene | No reduced progression to severe illness requiring hospitalization; CP did not reduce viral load change at day 7 | Vague definition of seropositivity, NA; reduction in methylene blue inactivation; no assessment of Fc-mediated functions | None |  |
| NCT04149949 (GIFV Early)            | 421 (out of 640) (1:1)                          | FFP                              | 0                                | ≤7 from symptoms                           | One 300 mL unit                               | 1:386                         | 9.9% sararagene | No difference in hospital admission, death or time to resolution (OR = 0.93) regardless of NAb titer | Moderately late usage, lower titers, lower hospitalization rate (9.3%), hence not powered to exclude a small treatment effect | Effect of CP on hospital admission or death was largest in patients with ≤7 days of symptoms (OR, 0.68) | 28, 29 |

(Continued on next page)
### TABLE 3 (Continued)

| RCT identifier (acronym/first author) | No. of participants recruited (out of expected) | Randomization strategy | Control arm (in addition to BSC) | Median days before randomization | Baseline recipient 10-point WHO score* (24, 25) | Transfused CCP vol (mL/pathogen inactivation) | Transfused CCP in CCP units | Median NAb titer in CCP units | Median pretransfusion NAb titer in recipient | Main outcomes reported in abstract or conclusions | Likely reasons for failure | Signals of efficacy | Reference |
|-------------------------------------|-------------------------------------------------|------------------------|---------------------------------|---------------------------------|---------------------------------------------|-----------------------------------------------|---------------------------------|---------------------------------|---------------------------------------------|-----------------------------------------------|---------------------------------|------------------|----------|
| NCT04193727 (CS-001)               | 417 (1:1)                                       | BSC >7 from radiological diagnosis | 4-5                             | Two 200-mL aliquots (<90% amotosalen; <10% biofilm inactivated) | 1:226 in each unit (>1:140) | NA                                | NA                              | No statistically significant improvement in progression to ventilatory support or death | Powered to detect an exaggerated 40% reduction in primary endpoint; underpowered for subgroup analysis; late usage; unexplained findings at site 2 (which recruited 40% of patients); late usage; no significant difference in no. of days of oxygen treatment to keep SaO2 > 95% or mortality by 28 days, clered for futility | Focusing on patients with worse clinical course (requiring oxygen at day 4 since NPS); largely underpowered; many patients had a P/F > 200 and symptoms to transfusion | 46 |
| NCT04094410 (CDP-2)                | 31 (out of 100: 1:1)                            | BSC <4 from positive NPS | 5                               | Three 200- to 250- mL aliquots | 1:116 in each unit; >1:40 | NA                                | NA                              | No significant difference in no. of days of oxygen treatment to keep SaO2 > 95% or mortality by 28 days, clered for futility | No failure | None |
| NCT04197675 (PennCCP2)             | 80 (1:1)                                        | BSC 6 since onset of symptoms, since hospitalization | 3-5                             | 2 units on day 1 from 2 different donors | NA | NA (99% seronegative) | Significant benefit by clinical severity score and 28-day mortality (24% vs 6%) in patients with a median of 3 comorbidities (including immunodeficiency) | No failure | None |
| NCT04373660 (CSSC-004)             | 1,223 (out of 1,344: 1:1)                      | FFP 6 since onset of symptoms (outpatients), since hospitalization | 1-3                             | One 250-mL unit | NA (1:14,980 Euroimmun) | NA                                | Hospitalization in 63.4% of FFP vs 29.9% of CCP (RR = 0.46) | No failure | None |
| NCT04144737 (CONTAIN)              | 941 (1:1)                                       | BSC + placebo 7 since onset of symptoms | 5                               | One 250-mL unit | 1:93 (70% < 1:160) | NA (67% seropositive) | No improvement in WHO ordinal scale at day 14 or 28 | Low-titer (except Q2 and Q5) and low-volume, centrally distributed CCP to states with different viral variants after June 2020, primary endpoint too early at day 14 | No failure | None |
| NCT04328010 (CSSC-001)             | 180 (out of 300: 1:1)                           | BSC + FFP 6 days since onset of symptoms | 6-9                             | 3 units of 600 mL each | 1:120 | 100% seronegative | No reduction in infection or symptomatic disease rate | Not powered to show reduction in hospitalization | No COVID-19-related hospitalizations in CCP recipients and 21% control recipients | No COVID-19-related hospitalizations in CCP recipients and 21% control recipients | 26 |
| RBC-744strf                          | 110 (out of 120: 1:1)                           | BSC 8 since onset of symptoms | 6-9                             | 3 units of 600 mL each | 1:120 | 100% seropositive | No statistically significant reduction in mortality, requirement for invasive ventilation, and duration of hospital stay | Very late usage | No COVID-19-related hospitalizations in CCP recipients and 21% control recipients | No COVID-19-related hospitalizations in CCP recipients and 21% control recipients | 112 |

*NAb: neutralizing antibodies; BSC, best supportive care; FFP, fresh frozen (nonconvalescent) plasma; NA, not assessed (i.e., antivirus antibodies were assessed only using high-throughput serology); IQR, interquartile range; OR, odds ratio; ARDS, acute respiratory distress syndrome; LDH, lactate dehydrogenase; CRP, C-reactive protein; PaO2, partial pressure of oxygen; FiO2, inhaled fraction of oxygen; CXR, chest X-ray; IVIg, intravenous Ig; P/F, PaO2/FiO2; ORs, cumulative adjusted odds ratio; n.r., not reached. Moderately late usage is defined as 4 to 6 days since onset of symptoms, late usage as 7 to 10 days, and very late usage as >10 days.

*Ten-point WHO scores: 0, uninfected, no viral RNA detected; 1, asymptomatic, viral RNA detected; 2, symptomatic, dependent; 3, symptomatic, assistance needed; 4, hospitalized, no oxygen therapy; 5, hospitalized, oxygen by mask or nasal prongs; 6, hospitalized, oxygen by NIV or high flow; 7, intubation and mechanical ventilation, pO2/FiO2 ≥ 150 or SpO2/FiO2 ≥ 200; 8, mechanical ventilation, pO2/FiO2 > 150, and vasopressors, dialysis, or ECMO; 10, dead.

*Powering to detect an exaggerated 40% reduction in primary endpoint; underpowered for subgroup analysis; late usage; unexplained findings at site 2 (which recruited 40% of patients); late usage; no significant difference in no. of days of oxygen treatment to keep SaO2 > 95% or mortality by 28 days, clered for futility | Focusing on patients with worse clinical course (requiring oxygen at day 4 since NPS); largely underpowered; many patients had a P/F > 200 and symptoms to transfusion | Trends for WHO score better than randomization at day 14 and 28, any use of mechanical ventilation or ECMO, duration of mechanical ventilation or ECMO use, and duration of supplemental oxygen use | None |

*Low-titer (except Q2 and Q5) and low-volume, centrally distributed CCP to states with different viral variants after June 2020, primary endpoint too early at day 14 | No failure | None |

*Low-titer (except Q2 and Q5) and low-volume, centrally distributed CCP to states with different viral variants after June 2020, primary endpoint too early at day 14 | No failure | None |

*At day 28, cORs were 0.72 for participants enrolled in Q2 (April–June 2020) and 0.65 for those not receiving remdesivir and not receiving corticosteroids at randomization, at day 28, mortality was lower in 496 seronegative than 242 seronegative participants irrespective of treatment arm, and in seronegative CCP (84% vs placebo (79%)); at day 60, rates were 31% for CCP and 35% for control recipients | No COVID-19-related hospitalizations in CCP recipients and 21% control recipients | No COVID-19-related hospitalizations in CCP recipients and 21% control recipients | 26 |

*NCT04364737 | RBR-744strf | 110 (out of 120: 1:1) because of inter-pandemic pause | 6-9 | 3 units of 600 mL each | 1:120 | 100% seropositive | No statistically significant reduction in mortality, requirement for invasive ventilation, and duration of hospital stay | Very late usage | At day 30, death rates were 22% for CCP group and 25% for control group; at days 60, rates were 31% for CCP and 35% for control | 112 |
Figure 2 graphically places the outcomes of RCTs and PSM studies on a Cartesian plot having timeliness and NAb dose as variables (if values are disclosed in the reports). This makes immediately clear that the studies suggesting benefit cluster in the lower right quadrant (high NAb dose and early intervention), while the studies showing no benefit are scattered elsewhere (Fig. 2A), reflecting lower antibody levels infused or late treatment, or both, with the latter being the more common problem. Nevertheless, when we focus on mortality irrespective of statistical significance (Fig. 2B) or focus on statistical significance (Fig. 2C), additional RCTs showed clear benefits.

THE INADEQUACY OF META-ANALYSES

With all the heterogeneity in key drivers discussed in the previous paragraphs, it becomes clear that secondary research (ranging from umbrella reviews to meta-analyses to systematic reviews), whereby each study is considered at the same level, invariably ends up with biased and divergent conclusions. This adds confusion to the already complex field of individual trial outcomes. Amazingly, as of 21 December 2021, PubMed has indexed 26 meta-analyses on CCP efficacy, more than the RCTs reported at the same date. Until the beginning of 2021, meta-analyses (variably including observational studies) were generally in favor of CCP (76) but began to be biased toward failure after publication of the large RECOVERY trial (50), which, by enrolling as many as 11,448 patients, diluted all the signals from positive RCTs. Clear examples of this phenomenon come from a widely cited meta-analysis from Janiaud et al. in JAMA (77), which included press release data from RECOVERY, and from the living systematic review by the Cochrane Group (78). The JAMA paper was surely unprecedented in the tradition of meta-analysis, not only because it included a study based only on a news release (which proved to differ in some important respects from the published paper), but because it allowed these data from a news release to dominate the entire analysis. In November 2021, in a follow-up meta-analysis from the same group on 16,477 patients from 33 trials, RECOVERY still accounted for 69.8% of the data (79). Several groups have attempted to dissect the RECOVERY trial and others by running subgroup analyses in their systematic reviews (80–82), but these reviews were unable to restore the confidence in CCP efficacy in the clinical community that had been lost because of the publication of the overall negative findings of RECOVERY and PlasmAr (83). Basing its recommendations entirely on RCT meta-analyses, on 8 December, the WHO revised its living guidelines on drugs for COVID-19, discouraging usage of CCP (84).

Meta-analyses embedding more recent studies and performing subgroup analysis were more positive for the beneficial effects of CCP. A meta-analysis of 22,591 patients (enrolled in 10 RCTs and 15 observational studies) showed that early CCP significantly reduced mortality (RR, 0.72; \( P < 0.00001 \)) but only in patients who were not suffering severe or critical disease (85). Another meta-analysis of 18 peer-reviewed clinical trials, 3 preprints, and 26 observational studies found that CCP use was associated with reduced risk of all-cause mortality in severe or critical COVID-19 patients (86). A recent umbrella review of 29 meta-analyses and systematic reviews found evidences for improvement in the CCP arms for some outcomes (overall mortality, viral clearance at day 3) but not for others (clinical improvement, length of hospital stay) (87).

Rather than pooling published RCTs, the Continuous Monitoring of Pooled International Trials of Convalescent Plasma for COVID-19 Hospitalized Patients (COMPILE) study pooled individual patient data from ongoing RCTs at 2-week intervals. Unfortunately, with the single exception of CONTAIN (26), participating RCTs largely treated patients in advanced disease stages (DAWN-plasma [34], PLACID [10], ConCOVID [36], ConPlas-19 [48], NCT04421404, PennCCP2 [88], and the Brasília Covid-19 Convalescent Plasma [BCCP]) (89). Not surprisingly, the COMPILE metanalysis failed to show any benefit from CCP in the aggregate analysis (90). Nevertheless, the investigators were able to derive a therapeutic benefit index (TBI) showing that CCP mostly benefits patients with preexisting conditions (diabetes and cardiovascular and pulmonary diseases), with blood type A or AB, and, most importantly, at early COVID-19 stage (91).
CURRENT CLINICAL UTILITY OF CCP

While CCP contains a plethora of biologically active molecules (92), we now have very strong evidence that appropriately vetted CCP from eligible convalescent donors is safe for patients (93, 94), with no evidence of increased risks of transfusion-transmitted acute lung injury or antibody-mediated enhancement concerns feared in the early days of the pandemic (95). Polyclonal antibodies such as are present in CCP are likely to offer better protection against onset of variants than monoclonal antibodies (96–98). Importantly, Pommeret et al. showed that CCP can rescue immune escape variants that emerged during treatments with a bamlanivimab/etesevimab cocktail (99). Outcomes in immunocompromised patients treated with CCP have been successful in the long term, with minimal evidence of immune escape (100).

We have also learned that CCP is less likely to benefit patients requiring oxygen (i.e., from level 4 and up on the WHO 11-point ordinal scale), and hence, ideally, the focus should be on outpatients and in identifying that subset of patients who seek hospital care and are still sufficiently early in the course of disease such that they can benefit from CCP. This finding parallels the finding with hyperimmune serum and anti-Spike monoclonal antibodies, which at first failed in hospitalized patients (101, 102) but later succeeded for ambulatory patients with mild to moderate COVID-19 (103) and were approved for emergency use.

CCP usage per admission peaked after issuance of the EUA, with more than 40% of inpatients estimated to have received CCP between late September and early November 2020. Oladunjoye et al. showed that mortality in the second wave in the United States, when utilization of corticosteroids, remdesivir, and convalescent plasma was higher, was lower than in the first wave (104). However, following reports of RCTs that failed to show clear benefit from CCP, usage per admission declined steadily to a nadir of less than 10% in March 2021. A strong inverse correlation (Pearson correlation coefficient of $-0.5176$ with a $P$ of 0.00242) was found between CCP usage and deaths occurring 2 weeks after admission, and this finding was robust for examination of deaths taking place 1, 2, or 3 weeks after admission. Changes in number of hospital admissions, prevalence of variants, and age of patients could not explain these findings. The authors estimated that the retreat from CCP usage, a phenomenon they termed “plasma hesitancy,” might have resulted in 29,000 to 36,000 excess deaths in the period from mid-November 2020 to February 2021 (105). The same analysis estimated that the United States had avoided 96,000 excess deaths from August 2020 to March 2021 by its liberal deployment of CCP.

Several lines of evidence, ranging from the EAP to clinical trials employing RCT or PSM controls, are now indicating how CCP should be used early in immunocompetent patients (106). Nevertheless, chronically immunosuppressed patients benefit from CCP even at later stages (100, 107, 108): the best evidence for this scenario comes from a prospective PSM study showing a halving of mortality in ICU-admitted oncohematological COVID-19 patients who received CCP (109). We note that while there have been concerns that use in the immunocompromised can promote the emergence of antibody-resistant variants, such variants have emerged from massive replication in susceptible populations and not from treated patients, who in any case are isolated in hospitals, where mitigation efforts to reduce transmission are employed, and are thus very unlikely to transmit their viruses further (110). Such simple concepts have been poorly communicated to the general public and the clinical community, who should be better informed on the settings where CCP has shown efficacy and the ones where it has not.

CONCLUSIONS

The absence of benefit in trials of CCP largely occurs for four reasons:

1. Trials that transfused insufficient therapeutic doses of CCP due to either low total IgG levels or low NAb levels (e.g., PLACID [10]).
2. Trials that transfused appropriate doses of CCP but too late, but which nevertheless reported signals of efficacy (e.g., RECOVERY [50], CAPSID [52], NCT04359810 [11], and TSUNAMI [46]).
3. Trials that were stopped too early to observe benefit or with inherent design flaws and/or were underpowered such that the likelihood of success was reduced (e.g., C3PO [27]).
4. Trials in which CCP was used to treat a condition not amenable to antibody intervention, such as hypoxia that is caused by pulmonary inflammation (e.g., COP20 [111], RBR-7f4mt9f [112], or REMAP-CAP [35]).

In contrast, trials showing a benefit were characterized by the initiation of CCP treatment as early as 44 to 72 h within onset of symptoms (which largely pertains to outpatients) and using CCP with a NAb titer of $>1:160$. Benefit within 1 week from onset of symptoms (including in hospitalized patients) is less well understood, although a benefit from higher therapeutic doses cannot be ruled out at this stage. Clinical benefit seems absent when administered after 1 week from onset of symptoms or in patients requiring ventilation or in those who receive CCP with a low NAb titer.

**RECOMMENDATIONS**

Stopping trials for futility is an occurrence that deserves special attention, because it represents wasted resources during a pandemic. Eight RCTs so far have been halted for futility, namely, RECOVERY (50), REMAP-CAP (35), CONCOR-1 (113), C3PO (27), NCT04361253 (ESCAPE), CoV-Early (28), ConV-ert (29), and COP20 (111), with the first one being viewed as the strongest evidence for futility (50), with its massive recruitment affecting the outcomes of systematic reviews (77). Instead of stopping trials for futility based on preset endpoints, we urge that data and safety monitoring boards (DSMBs) facing a high likelihood of lack of statistical significance provide advice on trial modifications that are likely to amplify the significance of signals of efficacy evident in these studies. This would seem a more responsible action than trial cessation, given the paucity of therapeutic alternatives in the pandemic emergency.

We also suggest that more flexibility is needed when dealing with a new virus, since estimates of efficacy and the required power can change tremendously as the data accumulate. For example, some RCTs were designed to evaluate efficacy at day 15, but subsequently, we learned that this time was too early since mortality often occurs later (26). Indeed, a Bayesian reanalysis of RECOVERY data with a wide variety of priors (vague, optimistic, skeptical, and pessimistic) calculated the posterior probability for both any benefit or a modest benefit (number needed to treat, 100). Across all patients, when analyzed with a vague prior, the likelihood of any benefit or a modest benefit was estimated to be 64% and 18%, respectively. In contrast, in the seronegative subgroup, the likelihood of any benefit or a modest benefit was estimated to be 90% and 74%, respectively (80). This finding of benefit accruing to specific subgroups, who were not determined post hoc but because they were likely to benefit based on an understanding of the principles of CP treatment, is found in nearly every trial whose overall finding is negative. This effect is more reflective of a problem with RCT design and execution than a limitation on the efficacy of CCP. Although we agree that subgroup analysis carries the risk of “cherry picking” data, such analyses are often important for hypothesis generation and are critically important during the emergency of a pandemic where neither viral pathogenesis nor therapeutic variables are well understood. When subgroup analyses are based on firm biological principles, such as focusing on those treated early in disease or lacking their own serological response, the exercise may be warranted. Christopher Columbus missed the prespecified primary endpoint of his mission, reaching India, but no one considers his discovery of the New World to be a failure! Turning to the clinical arena, most trials of anticoagulants in myocardial infarction found reductions in mortality of about 20 to 25%, which was generally not significant in these underpowered trials that declared the findings to be null, even though such a mortality reduction would clearly be of value (113). Given that conventional peer review slows down during a pandemic, prepublishing RCT results by the preprint mechanism should be encouraged to accelerate sharing of potentially life-saving therapeutic approaches and to provide prepublication review that could improve the quality of the final published study.
THE FUTURE OF CCP

CCP remains a relatively inexpensive therapy that is available throughout the world, even in resource-poor areas that cannot afford expensive antiviral drugs or monoclonal antibody therapies. Much has been learned about the variables that affect CCP efficacy, even though, as recounted here, the clinical efficacy data are mixed. Table 4 lists the RCTs whose outcomes have still to be reported after completion or which are still recruiting patients. Unfortunately, few new findings can be expected, given that most of these RCTs were designed to enroll patients having symptoms for more than 7 days. Given the heterogeneity of the product and the complex variables that contribute to efficacy, it is remarkable that many studies have reported reductions in mortality. This suggests a likely therapeutic effect that allow signals of efficacy to break through all the noise imposed by variability in the product and its clinical use. The positive evidence for CCP efficacy cannot be dismissed, while in many cases negative results can be explained. In the absence of good therapeutic options for COVID-19, CCP is likely to find a niche in the early treatment of disease. Instead of looking for unlikely superiority outcomes, noninferiority RCTs comparing MAbs with CCP in early arrivals should be initiated. Such an RCT is very unlikely to be sponsored by vendor companies, so public institutions should be sensitized to funding it.

There is evidence that vaccinated convalescents may have even higher NAb titers than unvaccinated convalescents (114, 115) and that these NAbs are more effective against VOCs than those from unvaccinated convalescents (116, 117), offering the promise of expanded success in using CCP. The higher frequency of high-titer donors would make donor screening more cost-effective. With these donations having been collected from individuals far from hospital discharge, and eventually from periodic blood donors, it is unlikely that these units would benefit from further infectious risk minimization with PRTs, reducing the final cost and avoiding the previously discussed potential problem of the inactivation method interfering with antibody function. Future CCP trials that will start after mass vaccination campaigns should preferentially rely on CCP from vaccinated donors. That said, inclusion of vaccinated individuals (e.g., CSSC-004 [30]) in future RCTs is also a potentially confounder. Indeed, those individuals are at lower risk, thus increasing the outpatient NNTT to prevent a single disease progression and also complicating the identification of seronegative individuals who are more likely to benefit from NAbs.

Low- to middle-income countries (LMIC) are likely to benefit the most from CCP, given that they cannot afford massive deployment of MAbs or small-chemical antivirals. Research is ongoing to spare some of the cold chain requirements for CCP reliance over freeze-dried plasma (FDP), which has been shown to preserve NAb functions for months at ambient temperature (118).

On 8 November 2021, the sudden emergence of the SARS-CoV-2 Omicron VOC with its 32 Spike mutations was an alarming development because it threatened to prolong the pandemic and undermine the immunity gains made with vaccination campaigns. Computer modeling and in vitro VNTs soon confirmed full escape from clinically used MAb cocktails (including bamlanivimab plus etesevimab, REGN-CoV-2, and AZD7442) (119, 120). While it was already known that MAb cocktails were less likely to experience immune escape than single MAbs, most of the scientific community underestimated the risk from major shifts in the three-dimensional Spike structure. Combined with the lengthy manufacturing and approval process for MAb therapies, such sudden shifts largely hinder primarily MAb-based therapies, since polyclonal approaches such as CCP are less vulnerable to losing activity. While even CCP is vulnerable to losing some efficacy with VOCs that manifest partial immune escape, the probability and extent of reduction are far lower (121). In view of this, on 27 December 2021, the FDA updated the EUA expanding authorization to immunosuppressed outpatients (122).

Given the experience accumulated with COVID-19, it is almost certain that CCP will again be considered to deal with the surges yet to come in the current epidemic as well as for the next epidemic. One of the good legacies of the COVID-19 pandemic is that an enormous international research effort had produced a large body of data that teaches how to best use CCP. The lessons learned reinforce the experience of the past, namely that best results are obtained with high-titer CCP administered early in the course of disease. We are hopeful
| Status                        | NCT registration no.                  | Patient subtype                                                                 | Control arm                  | Study design                                                                 | No. planned to enroll | Study start date      | Location       |
|-------------------------------|--------------------------------------|---------------------------------------------------------------------------------|------------------------------|-------------------------------------------------------------------------------|-----------------------|------------------------|-----------------|
| Completed                     | NCT04332835                          | Severe (SOFA < 6)                                                              | BSC                          | Single masking (outcome assessor)                                             | 92                    | 8 August 2020          | Colombia       |
|                               | NCT04349410                          | Any                                                                            | Placebo                      | Single masking (investigator)                                                 | 1,800                 | 11 April 2020          | USA            |
|                               | NCT04421404                          | Within 3 days from hospitalization or 14 from symptoms                        | Placebo                      | Triple masking (participant, care provider, investigator)                    | 34                    | 9 June 2020            | USA            |
|                               | NCT04374526                          | Pneumonia, age ≥ 65 yrs, and PaO₂/FiO₂ ≥ 300 mm Hg and comorbidities       | BSC                          | Open label                                                                   | 29                    | 27 May 2020            | Italy           |
|                               | NCT04357873                          | Hospitalized requiring supplemental oxygen                                  | BSC                          | Quadruple masking (participant, care provider, investigator, outcome assessor)| 30                    | 27 April 2020          | Mexico          |
|                               | NCT04405310                          | Moderate to severe requiring supplemental oxygen                             | Albumin                      | Double (participant, care provider)                                           | 80                    | 20 May 2020            | Mexico          |
|                               | NCT04425915                          | On ventilator within 3 days from onset of symptoms                           | BSC                          | Open label                                                                   | 400                   | 14 June 2020          | India           |
| Active, not recruiting        | NCT04539275                          | Ventilated and within 3 days from hospitalization                          | Masked saline placebo        | Triple masking (participant, care provider, investigator)                    | 702                   | 16 November 2020       | USA            |
|                               | NCT04374487                          | Hospitalized and severe                                                      | BSC                          | Open label                                                                   | 100                   | 9 May 2020             | India           |
|                               | NCT04425837                          | High-risk                                                                      | BSC                          | Single masking (outcome assessor)                                             | 236                   | July 2020              | Colombia        |
|                               | NCT04395170                          | Hospitalized                                                                  | 2 arms (BSC, anti-COVID-19   | Open label                                                                   | 75                    | September 2020         | Colombia        |
|                               | NCT04391101                          | Severe                                                                         | BSC                          | Open label                                                                   | 231                   | June 2020              | Colombia        |
| Recruiting                    | NCT045168411                         | Moderate to severe                                                            | Placebo                      | Triple masking (participant, care provider, investigator)                    | 600                   | 21 September 2020      | South Africa    |
|                               | NCT04388410                          | Hospitalized, severe disease or risk for severe diseases                     | BSC                          | Quadruple masking (participant, care provider, investigator, outcome assessor)| 410                   | 25 August 2020         | Mexico          |
|                               | NCT04385403                          | Severe infection                                                              | BSC                          | Open label                                                                   | 400                   | 1 May 2020             | Italy           |
|                               | NCT043854935                         | Acute respiratory distress syndrome                                            | BSC                          | Open label                                                                   | 60                    | 18 May 2020            | Indonesia       |
|                               | NCT04362176                          | Hospitalized adults                                                           | Placebo                      | Triple masking (participant, care provider, investigator, outcome assessor)  | 1,000                 | 24 April 2020          | USA            |
|                               | NCT04390503                          | Exposed within 7 days or mild symptoms within 5 days                         | Albumin                      | Double masking (participant, outcome assessor)                               | 150                   | 12 March 2021          | USA            |
|                               | NCT04376034                          | Severe or life-threatening                                                   | BSC                          | Open label                                                                   | 240                   | 30 March 2021          | USA            |
|                               | NCT04366245                          | Hospitalized, ventilated                                                     | BSC                          | Open label                                                                   | 72                    | 23 April 2020          | Spain           |
|                               | NCT04333251                          | Hospitalized within 7 days from symptoms                                     | BSC                          | Open label                                                                   | 115                   | 1 April 2020           | USA            |
|                               | NCT04345991                          | Mild and within 8 days from symptoms                                         | BSC                          | Open label                                                                   | 120                   | 15 April 2020          | France          |
|                               | NCT04372979                          | Hospitalized within 10 days from symptoms                                    | FFP                          | Triple masking (participant, care provider, investigator, outcome assessor)  | 80                    | 14 September 2020      | France          |
|                               | NCT04345289                          | Adults with pneumonia                                                        | Placebo                      | Quadruple masking (participant, care provider, investigator, outcome assessor)| 1,100                 | 1 May 2020             | Denmark         |

*BSC, best supportive care; FFP, fresh frozen plasma. Several studies were withdrawn (NCT04377568).
that lessons learned in this pandemic are heeded such that use and trials focus on the very early use of high-titer CCP.

ACKNOWLEDGEMENTS

This article was written in memory of Giuseppe De Donno, Director of the Pneumology Division at the Mantua Hospital, a pioneer in the field of CCP.

Author contributions: D.F. designed the paper, analyzed the data, and wrote the first draft. M.F., M.J.J., T.B., L.P., N.P., and A.C. revised the manuscript. All authors approved the final version.

We declare no conflict of interest.

REFERENCES

1. Casadevall A, Pirofski LA, Joyner MJ. 2021. The principles of antibody therapy for infectious diseases with relevance for COVID-19. mBio 12:e00372-20.
2. Casadevall A, Pirofski LA. 2020. The convalescent sera option for containing COVID-19. J Clin Invest 130:1545–1548. https://doi.org/10.1172/JCI138003.
3. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. 2020. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 38:e66–e73. https://doi.org/10.1097/CCM.0000000000003840.
4. Duan K, Liu B, Li C, Zhang H, Yu T, J Zhou, Chen M, Meng S, Hu Y, Peng C, Yuan M, Li G, Han J, Wang Z, Yu Y, Wang X, Yu D, Xu L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X. 2020. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 117:9490–9496. https://doi.org/10.1073/pnas.2004168117.
5. Li L, Zhang W, Hu Y, Tong X, Zhang Y, Jiang J, Yong K, Ren L, Wei Q, Mei H, Hu C, Tao C, Yang R, Wang J, Yu Y, Guo Y, Wu X, Xu Z, Zeng L, Xiong N, Chen L, Wang J, Man N, Liu Y, Xu H, Deng E, Zhang X, Li C, Li C, Wang C, Su S, Zhang L, Wang J, Wu Y, Liu Z. 2020. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 324:460–470. https://doi.org/10.1001/jama.2020.10044.
6. Perotti C, Baldanti F, Bruno R, Delfante C, Seminari E, Casari S, Percivaille E, Gilingani E, Musella V, Belliato M, Garuti M, Meloni F, Frigato M, Di Sabatino A, Kelsey C, De Donno G, Franchini M. 2020. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial. Haematologica 105: 2834–2840. https://doi.org/10.3324/haematol.2020.261784.
7. Focosi D, Anderson AO, Tang JW, Tuccori M. 2020. Convalescent plasma therapy for COVID-19: state of the art. Clin Microbiol Rev 33:e00072-20. https://doi.org/10.1128/CMR.00072-20.
8. Joyner MJ, Carter RE, Klompas AM, Wiggins CC, Shepherd JR, Rea RF, Whelan ER, Clayburn AJ, Spiegel MR, Johnson PW, Lesser ER, Baker SE, Larson KF, Ruey Y, Wu X, Verma A, Lakshmanappa YS, Schmidt BA, Gunthard HF, Manz MG, Trkola A. 2021. Contribution of endogenous and exogenous antibodies to clearance of SARS-CoV-2 during convalescent plasma therapy. medRxiv. https://doi.org/10.1101/2021.12.09.21267513.
9. Simonovich VA, Burgess Pratt LD, Scibona P, Benitez MV, Vallone MG, Vázquez C, Savoy N, Giunta DH, Pérez LG, Sánchez ML, Gamarikov AV, Ojeda DS, Santoro DM, Camino PJ, Antelo S, Rainero K, Viellida GP, Miyazaki E, Corinnett W, Trabadole OA, Ross FM, Spotti M, Funtovich G, Scordo WE, Losso MH, Ferniott I, Pardo PE, Rodriguez E, Rucci P, Pasquali J, Fuentes NA, Esperatti M, Speroni GA, Nannini EC, Matteaccio A, Michelangelo HG, Follmann D, Lane HC, Belloso WH, PlasmaR Study Group. 2021. A randomized, double-blind, controlled trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med 384:619–629. https://doi.org/10.1056/NEJMoa2031304.
10. Casadevall LA. 2020. Pathogenesis of COVID-19 from the perspective of the damage-response framework. mBio 11:e01175-20. https://doi.org/10.1128/mBio.01175-20.
11. Marconato M, Ábelia IA, Hauser A, Schwarzmüller M, Katzensteiner R, Braun DL, Epp S, Audige A, Weber J, Rusert P, Schindler E, Pasquale F, Casteleiro V, Schierl C, Kunert V, Huber M, Zahner M, Schmutz S, Frey BM, Koutsouk A, Bihambo P. 2021. Lack of association between convalescent plasma therapy and COVID-19 clinical severity. JCI Insight 13:e150646. https://doi.org/10.1172/jci.insight.150646.
COVID19 Convalescent Plasma
Clinical Microbiology Reviews

A, Liu S, Lee B, Krammer F, Zsilla-Pozner S, Hieoe CE. 2021. Role of IgM and IgA antibodies in the neutralization of SARS-CoV-2. J Infect Dis 223: 957–970. https://doi.org/10.1093/infdis/jiaa784.

41. Egloff SAA, Junglen A, Restivo JSA, Wongskhaluang M, Martin C, Doshi P, Menichetti F, Popoli P, Puopolo M, Spila Alegiani S, Tiseo G, Bartoloni A, Liu S, Lee B, Krammer F, Zolla-Pazner S, Hioe CE. 2021. Role of IgM and IgA antibodies in the neutralization of SARS-CoV-2. J Infect Dis 223: 957–970. https://doi.org/10.1038/s41467-021-25113-5.

42. Koeper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman VM, Gruener B, Ernst L, Spieth P, Lepper PM, Bentz M, Zinn S, Paul G, Kalbhen N, Dollinger M, Rosenberger P, Kirschning T, Thiele T, Apfel T, Mayer B, Schmidt M, Drosten C, Wulf H, Kruse JM, Junghwirth B, Seifried E, Schneeberger H, CAPSID Clinical Trial Group. 2021. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. J Clin Invest 131:e1552264. https://doi.org/10.1172/JCI1552264/2021.05.12156192.

43. Kunze KL, Johnson PW, van Helmond N, Senefeld JW, Petersen MM, Klassen SA, Wiggins CC, Klompas AM, Bruno JR, Mills JR, Theel ES, Buras MR, Golshafar MA, Sexton MA, Diaz Soto JC, Baker SE, Shepherd JRA, Verdun NC, Marks P, Paneth NS, Fairweather D, Wright RS, van Buskirk CM, Winters JL, Stubbs JR, Senese KA, Pletsch MC, Buchholz ZA, Rea RF, Heravesich V, Whelan ER, Clayton AJ, Larson KF, Ripoll JG, Andersen KJ, Lesser ER, Vogt MNP, Dennis JJ, Regimbald RJ, Bauer PR, Blair JE, Casevale A, Carter RE, Joyner MJ. 2021. Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors. Nat Commun 12:4864. https://doi.org/10.1038/s41467-021-25113-5.

44. Rochman ND, Wof V, Faure G, Mutz P, Zhang F, Koonin EV. 2021. Ongoing global and regional adaptive evolution of SARS-CoV-2. Proc Natl Acad Sci U S A 118:e202104441118. https://doi.org/10.1073/pnas.2104411118.

45. Focosi D, Tuccori M, Baj A, Maggi F. 2021. SARS-CoV-2 variants: a synopsis of in vitro efficacy data of convalescent plasma, currently marketed vaccines, and monoclonal antibodies. Viruses 13:1211. https://doi.org/10.3390/v13071211.

46. Dukovic D, Duivik A, Becker M, Wagner TR, Kaiser PD, Traenkle B, Rothbauber U, Kienzel K, Bunk S, Strümpfer C, Häberle H, Schmauder K, Malek N, Althaus K, Kiepenbein M, Götz S, Schneiderman-Marra N. 2021. Reduced serum neutralization capacity against SARS-CoV-2 variants in a multiplex ACE2 RBD competition assay. medRxiv. https://doi.org/10.1101/2021.08.21.21262328.

47. Bennett-Guerrero E, Rromeier JL, Talbot LR, Ahmad T, Momalone LJ, Singh SM, Hearring JC, Lawler H, Holoprosad DD, Freedomen AT, Carter JA, Browne JW, Cosgrove ME, Shevick ME, Generale LM, Andrew MA, Nachman S, Fries BC. 2021. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York: a double-blind randomized trial. Crit Care Med 49:1015–1025. https://doi.org/10.1097/CCM.0000000000008966.

48. Bajpai M, Kumar S, Mutheshwari A, Chhabra K, Karl P, Gupta A, Narayanan A, Gupta E, Trehanapati N, Bihari C, Agarwal R, Gupta K, Gupta U, Bhadrawt A, Kumar G, Islam M, Singh R, Yadav P, Maiwall R, Sarin SK. 2020. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. medRxiv. https://doi.org/10.1101/2020.05.20.21253937.

49. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Petrou L, Campbell M, Pessoa-Amorim G, Spata E, staplin N, Emberson JR, Prudon B, Hine P, Brown T, Green CA, Sarkar D, Resal P, Yates B, Biewick T, Bischer F, Selton F, Bhiilke JJ, Bichu MH, Chapelle CL, Day JN, Faust SN, Jaki T, Jeffry K, Juszczak E, Lim WS, Montgomery AO, Mufomd A, Rowan K, Thwaites G, Weinreich DM, Haynes R, Landray MJ. 2021. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. https://doi.org/10.1101/2021.06.15.21258542.

50. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell S, Staplin N, Brightling C, Ustianowski A, Elmalı E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chapell CL, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baille JL, Haynes R, Landray MJ. 2021. Muxasmethone in hospitalized patients with COVID-19. N Engl J Med 384:693–704. https://doi.org/10.1056/NEJMoa2124136.

51. Senefeld JW, Johnson PW, Kunze KL, Bloch EM, van Helmond N, Golshafar MA, Klassen KA, Klompas AM, Sexton MA, Diaz Soto JC, Grossman BJ, Tobian AAR, Goel R, Wiggins CC, Bruno KA, van Buskirk CM, Stubbbs JW, Winters JL, Casevale A, Paneth NS, Shaz BH, Petersen MM, Sachs B, Buras MR, Wieczorek MA, Russoniello B, Dumont JL, Baker SE, Vaisselino RL, Shepherd JRA, Young PP, Verdun NC, Marks P, Haley NR, Rea RF, Katz L, Heravesich V, Waxman DA, Whelan ER, Bergman A, Clayton AJ, Grabowski MK, Larson KF, Ripoll JG, Andersen KJ, Vogt MNP, Dennis JJ, Regimbald RJ, Bauer PR, Blair JE, et al. 2021. Access to and safety of COVID-19 convalescent plasma in the United States expanded Access Program: a national registry study. PLoS Med 18:e1003872. https://doi.org/10.1371/journal.pmed.1003872.

52. Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, Wiggins CC, Bruno KA, Klompas AM, Lesser ER, Kunze KL, Sexton MA, Diaz Soto JC, Baker SE, Shepherd JRA, van Helmond N, van Buskirk CM, Winters JL, Stubbs JR, Rea RF, Hodge DO, Heravesich V, Whelan ER, Clayton AJ, Larson KF, Ripoll JG, Andersen KJ, Lesser ER, Vogt MNP, Dennis JJ, Regimbald RJ, Bauer PR, Blair JE, Paneth NS, Fairweather D.
Shenoy AG, Hettinger AZ, Fernandez SJ, Blumenthal J, Baez V. 2021. Early significantly decreased mortality. Am J Pathol 190:2290–2303.

Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, Lopez BV, Egger TN, Yi X, Zhao P, Rogers J, Shehabedlin A, Joseph D, Leveque C, Olsen RJ, Bernard DW, Golilhar J, Musser JM. 2020. Treatment of COVID-19 in patients with convalescent plasma containing high-titer anti-serve respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein IgM. Am J Pathol 191:90–97. https://doi.org/10.1016/j.ajpath.2020.08.001.

Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Torrnye CA, Desruessmes MS. 2021. Early but not late convalescent plasma is associated with better survival in moderate to severe COVID-19. PLoS One 16:e254533. https://doi.org/10.1371/journal.pone.0254533.

Shenoy AG, Hettinger AZ, Fernandez SJ, Blumenthal J, Baez V. 2021. Early mortality benefit with COVID-19 convalescent plasma: a matched control study. Br J Haematol 192:706–713. https://doi.org/10.1111/bjh.17272.

Arnold Egloff SA, Junglen A, Restivo JSA, Wongshkualuang M, Martin C, Doshi P, Schlauch D, Formell S, Sears LE, Correll M, Burris HA, LeMaistre FR, Amato MP, Cattelan A, Guarnieri G, Monticelli J, Gonzalez SE, Regairaz L, Salazar M, Ferrando N, Gonzalez V, Carrera M, Li Y, Ruiz R, Thota R, Barnhill J, Goldstein DY, Uhlenger J, Garforth SJ, Almo SC, Lai JR, Gil MR, et al. 2021. Treatment of severe COVID-19 with convalescent plasma: one year of data from the Veneto region (Italy) Registry. Eur J Med 87:111–119. https://doi.org/10.1016/j.ejmech.2021.04.002.
99. Pommeret F, Colomba J, Bigenwald C, Laparra A, Bockel S, Bayle A, Guigon A, Faure E, Lemaire C, Chopin M, Tinez C, Assaf A, Lazrek M, Franchini M, Cruciani M. 2021. How safe is COVID-19 convalescent plasma? Diagnostics 11:1663. https://doi.org/10.3390/diagnostics11091663

100. Anonymous. 2021. CoVIg-19 Plasma Alliance announces topline results from NIH-sponsored clinical trial of investigational COVID-19 hyperimmune globulin medicine. https://www.takeda.com/newsroom/newsreleases/2021/covig-19-plasma-alliance-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-hyperimmune-globulin-medicine/. Accessed 2 April 2022.

101. Anonymous. 2021. Mortality due to COVID-19 infection: a comparison of first and second waves. J Community Hosp Intern Med Perspect 11:747–752. https://doi.org/10.1002/jchimp.2021.06.011

102. Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Paneth N, Carter R. 2021. Convalescent plasma use in the United States was inversely correlated with COVID-19 mortality: did convalescent plasma hesitancy cost lives? Elife 4:e69866. https://doi.org/10.7554/eLife.69866.

103. Focosi D, Franchini M, Pirofski L-a, Burntouf F, Fairweather L, Joyner MJ, Casadevall A. 2021. COVID-19 convalescent plasma therapy: hit fast, hit hard! Vox Sang 116:935–942. https://doi.org/10.1055/a-13104-021-05847-7

104. Olnes S, Epperson J, Olgren D, Qaouid S, Tarr P, Glazier P, Pasnik P, Alapudugari P, Donato A. 2021. Mortality due to COVID-19: a comparison of first and second waves. J Community Hosp Intern Med Perspect 11:747–752. https://doi.org/10.1002/jchimp.2021.06.011

105. Focosi D, Franchini M. 2021. COVID-19 convalescent plasma therapy: hit fast, hit hard! Vox Sang 116:935–942. https://doi.org/10.1055/a-13104-021-05847-7

106. Focosi D, Franchini M. 2021. COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: a narrative review. Transfus Hematol 55:130378. https://doi.org/10.1016/j.transci.2021.153071

107. Focosi D, Franchini M. 2021. COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: a narrative review. Transfus Hematol 55:130378. https://doi.org/10.1016/j.transci.2021.153071

108. Focosi D, Franchini M. 2021. COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: a narrative review. Transfus Hematol 55:130378. https://doi.org/10.1016/j.transci.2021.153071

109. Focosi D, Franchini M. 2021. COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: a narrative review. Transfus Hematol 55:130378. https://doi.org/10.1016/j.transci.2021.153071

110. Casadevall A, Henderson J, Joyner M, Pirofski L-a. 2021. SARS-Cov2 variants: the next wave of the COVID-19 pandemic. JAMA Oncol 7:1189. https://doi.org/10.1001/jamaoncol.2021.1799

111. Holm K, Lundgren M, Kjeldsen-Kragh J, Ljungquist O, Bottiger B, Wiken C, Oberg J, Fernstrom N, Rosendal E, Overby A, Bystrom J, Forsell M, Landin-Olsson M, Tiberghien P, Marot S, Jary A, Lacombe K, Vetens K, Sandbring B, Olofsson J, Bengtsson E, Landsman H, Lindemuth E, Gouma S, Mullin A, Barilla H, Pronina A, Invin L, Thomas R, Eichinger R, Demuth F, Prak E, Pascal J, Short W, Elvistov M, Baron J, Meyer N, Degnan K, Frank I, Hensley S, Siegel D, Tebas P. 2021. A randomized, controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest 131:e155114. https://doi.org/10.1172/JCI155114

112. De Santis GC, Oliveira LC, Garibaldi PMM, Almado CEL, Croda J, Arancio GG, Oliveira E, Torchio D, Langhi DM, Bordin JD, Gilo RR, Palma LC, Santos EV, Haddad SK, Prado BPA, Jr, Pontelli MC, Gomes R, Miranda CH, Martins MA, Covas DT, Arruda E, Fonseca BAL, Calado RT. 2022. High-Dose Convalescent Plasma for Treatment of Severe COVID-19. Clin Microbiol Rev 2022 May 27;35(3):1012.100200-26
to SARS-CoV-2 in Chile. Sci Adv 7:eabe6855. https://doi.org/10.1126/sciadv.aabe6855.

139. Dieterle ME, Haswanter D, Bortz RH, 3rd, Wirchanski AS, Lasso G, Vergnonole O, Abbasi SA, Fels JM, Lauderichil M, Florcz C, Mengotto A, Kimmel D, Malonos RJ, Georgiev G, Quiriz J, Barnhill J, Pirofski L, Daily JP, Dye JM, Lai JR, Herbert AS, Chandran K, Jangra RK. 2020. A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition. Cell Host Microbe 28:486–496.e6. https://doi.org/10.1016/j.chom.2020.06.020.

140. Jiang W, Li W, Xiong L, Wu Q, Wu Y, Hu B, Shen J, Pang R, Luo T, Guo Y, Yang Y, Han Y, Dai W, Zhu P, Xia X. 2020. Clinical efficacy of convalescent plasma therapy on treating COVID-19 patients: evidence from matched study and a meta-analysis. Clin Transl Med 10:e259. https://doi.org/10.1002/ctm2.259.

141. Pappa V, Boucha A, Terpos E, Thomopoulos TP, Rosati M, Stellas D, Antoniadou A, Mentis A, Papageorgiou SG, Politou M, Kotanidou A, Kalomenidis I, Poulakou G, Jahaj E, Kromopiko E, Grigopoulou S, Hu X, Bear J, Karaliota S, Bums R, Pagoni M, Trontzas I, Grouzi E, Labropoulos M, Stamoulis K, Bamias A, Tsididas S, Felber BK, Pavlakis GN, Dimopoulos MA. 2021. A phase II study on the use of convalescent plasma for the treatment of severe COVID-19—a propensity score-matched control analysis. Microorganisms 9:806. https://doi.org/10.3390/microorganisms9040806.

142. Salazar EZ, Kuchipudi SV, Christensen PA, Eager T, Yi X, Zhao P, Jin Z, Long SW, Olsen RJ, Chen J, Castillo B, Leveque C, Towers D, Lavinder J, Pavlakis GN, Dimopoulos MA. 2020. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. J Clin Invest 130:6728–6738. https://doi.org/10.1172/JCI141206.

143. Tworek A, Jaros K, Uzytska-Kaluzha B, Rydzewski A, Gil R, Depta A, Wierzb Z, Waczynski K, Zrdl ZJ, Rydzewska G. 2021. Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients—propensity score matched case-control study. Int J Infect Dis 105:209–215. https://doi.org/10.1016/j.ijid.2021.02.054.

144. Cristelli MP, Junior DML, Viana LA, de Andrade LGM, Martins SBS, Dreige SW, Olsen RJ, Chen J, Castillo B, Leveque C, Pavlakis GN, Dimopoulos MA. 2021. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. J Clin Investig 130:6728–6738. https://doi.org/10.1172/JCI141206.

145. Chauhan L, Pattee J, Ford J, Thomas C, Lesteberg K, Richards E, Lui M, Dumont LJ, Annen K, Berg M, Zirbes M, Miller A, Jenkins TC, Bennett TD, Antionadou A, Mentis A, Papageorgiou SG, Politou M, Kotanidou A, Kalomenidis I, Poulakou G, Jahaj E, Kromopiko E, Grigopoulou S, Hu X, Bear J, Karaliota S, Bums R, Pagoni M, Trontzas I, Grouzi E, Labropoulos M, Stamoulis K, Bamias A, Tsididas S, Felber BK, Pavlakis GN, Dimopoulos MA. 2021. A phase II study on the use of convalescent plasma for the treatment of severe COVID-19—a propensity score-matched control analysis. Microorganisms 9:806. https://doi.org/10.3390/microorganisms9040806.

146. Rasheed AM, Fatak DF, Hashim HA, Mauuold MF, Kabab K, Amsuda YA, Abdulamir AM. 2020. The therapeutic potential of convalescent plasma convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez Med 28:357–366.

147. Balcells ME, Rojas L, Le Corre N, Martínez-Valdebenito C, Ceballos ME, Zaccari K, Cotta K, Walecka I, Cicha M, Wierzba W, Zaczyłka A, Rydzewski A, Gil R, Depta A, Wierzb Z, Waczynski K, Zrdl ZJ, Rydzewska G. 2021. A randomized phase II clinical trial. PLoS Med 18:e1003415. https://doi.org/10.1371/journal.pmed.1003415.

148. Joyner MJ, Paneth NS, Senefeld JW, Faireweather D, Bruno KA, Wright RS, Carter RE, Casadevall A. 2022. Concerns about estimating relative risk of death associated with convalescent plasma for COVID-19. Nat Med 28:51–52. https://doi.org/10.1038/s41591-021-01638-6.

149. Anonymous. 2021. National COVID19 Convalescent Plasma Project. Commentary from the COVID-19 Convalescent Plasma Project (CCPP19) Leadership Group on “Early convalescent plasma for high-risk outpatients with COVID-19”. https://ccpp19.org/news/review%20of%20NEJM%20US%20outpatient%20cohort Accessed 25 August 2021.

150. Anonymous. 2 March 2021. NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms. https://www.nih.gov/news-events/news-releases/nih-halts-trial-covid-19-convalescent-plasma-emergency-department-patients-mild-symptoms.

151. Devos T, Geuken T, Schauwvliege A, Arien KS, Barbezange C, Cleeren M, Compenorval V, Daubey N, Desmetch D, Grimaldi D, Lambrecht BN, Luyten A, Maes P, Mountsch M, Romano M, Seley L, Neversignor MS, Vandenbergehe K, van Griensven J, Vebeke G, Vliege E, Yombi JC, Liesenborghs L, Verbeke G, Vlieghe E, Meyfroidt G. 2020. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 21:981. https://doi.org/10.1186/s13063-020-04876-0.

152. Franchini M, Focosi D, Casadevall A, Joyner MJ, Perotti C. 2022. Convalescent plasma for COVID-19: TSUNAMI is not the final word. Eur J Intern Med https://doi.org/10.1016/j.ejim.2022.01.016.

Daniele Focosi is a hematologist employed since 2009 as a resident transfusion physician at the Fisa University Hospital. He was formerly a transplant immunologist and immunogeneticist and a quality assurance manager at the largest blood bank in Italy. He has received awards from the European Federation of Immunogenetics, the European Society of Organ Transplantation, and the Italian Society of Hematology. He has a Ph.D. degree in clinical and fundamental virology and a master’s degree in clinical virology. He has authored 169 articles on topics ranging from emerging viral infections to new markers of immune competence (including more than 50 articles and a SpringerNature book on SARS-CoV-2 evolution), for an h-index of 30.

Massimo Franchini specialized in hematology (1995) at the University of Verona (Italy). He is currently Director of the Department of Hematology and Transfusion Medicine of the Hospital of Mantua (Italy). He is Associate Editor of Seminars in Thrombosis and Hemostasis and Member of the Committee of the Italian Association of Hemophilia Centers (AICE) for the revision of the Italian Guidelines on the Management of Hemophilia. He is a member of the Regional Hematology Network (REL, Lombardy Region), Sub委员会 of Hemostasis, and served as a consultant to the Italian Ministry of Health—National Blood Center (2016 to 2020). His field of scientific research is predominantly dedicated to hemostasis and thrombosis. He is currently studying the COVID-19 convalescent plasma, from biological validation to its clinical use. He has authored more than 650 publications for a h-index of 83.
Liise-anne Pirofski is a physician-scientist. Her research programs focus on immunity to encapsulated pathogens and antibody-mediated immunity to infectious diseases. She is chief of the Division of Infectious Diseases and the Jacques and Selma Mitrani Chair in Biomedical Research at Albert Einstein College of Medicine and Montefiore Medical Center. She is a member of the American Association of Physicians and a fellow of the American Academy of Microbiology, the American College of Physicians, the Infectious Diseases Society of America, and the American Association for the Advancement of Science. She is deeply devoted to biomedical education and mentoring, for which she has received numerous accolades, including the American Society for Microbiology William A. Hinton Award, the Albert Einstein College of Medicine Faculty Mentoring Award, the Harry Eagle Award for Outstanding Basic Science Teaching, and the Lifetime Achievement Award from the Albert Einstein College of Medicine Alumni Association.

Thierry Burnouf is a protein biochemist who has authored more than 280 publications in the field of therapeutic blood products for an h-index of 53. He has received the 2019 Award from the International Plasma Fractionation Association. His current research interest focuses on platelet growth factors for regenerative medicine and cell therapy, plasma fractionation, viral inactivation technologies, and blood biotechnology. He is the Secretary of the Working Party on Global Blood Safety and the Treasurer of the Working Party on Cellular Therapies of the International Society of Blood Transfusion.

Nigel Paneth is a pediatrician and perinatal and child health epidemiologist with a particular interest in the causes and prevention of childhood neurodevelopmental handicaps, especially cerebral palsy. He was among the promotors of the U.S. National COVID19 Convalescent Plasma Project (CCPP10). He is Emeritus University Distinguished Professor of Epidemiology and Biostatistics and Pediatrics at Michigan State University and has authored more than 320 publications for an h-index of 86.

Michael J. Joyner has authored more than 535 publications for an h-index of 93. His laboratory is interested in how humans respond to various forms of physical and mental stress during activities such as exercise, hypoxia, standing up, and blood loss. Dr. Joyner is leading a national program sponsored by the U.S. Government to coordinate the collection and distribution of COVID-19 convalescent plasma for the treatment of individuals with severe or life-threatening disease.

Arturo Casadevall is the Chair of the Molecular Microbiology & Immunology Department, Bloomberg Distinguished Professor, and Alfred & Jill Sommer Professor and Chair Professor at the Johns Hopkins School of Public Health. He has authored more than 900 PubMed-indexed articles for an h-index of 133. His research focuses on host defense mechanisms, how fungi cause disease, and the development of antibody-based therapies for infectious diseases.